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CHAPTER I 
 
INTRODUCTION 
 
Mental illness incidence rates have skyrocketed in the United States and globally over 
the past decade. According to the latest statistics of the National Institute of Mental Health, 
over 26 percent of Americans ages 18 and older suffer from a diagnosable mental disorder in 
a given year. Evidence from the World Health Organization suggests that nearly half the 
world’s population are affected by mental illness, with a negative impact on self-esteem, 
interpersonal relationships, and ability to function in daily life. Moreover, emotional health 
directly influences individual’s physical health and can lead to increased crime rates and 
substance abuse. Mental illness has become the leading cause of disability worldwide – the 
total costs of brain disorders exceed $3 trillion. It is apparent that the global community is 
facing a socioeconomic “ticking bomb” as people succumb to brain disorders. This becomes 
particularly relevant in times of global economic downturn. In a globalized world, recession-
associated increased unemployment, stagnant wages, poverty, and economic distress tightly 
correlate with increased suicide rates and the prevalence of mental illness. Therefore, 
appropriate diagnosis and treatment are critical components in the global fight against 
mental illness. Adequate mental health care is primarily complicated by poor access and ever-
increasing complexity of molecular mechanisms underlying mental illness. Indeed, the 
breakneck pace of technological progress has revolutionized our understanding and 
perception of mental illness and permitted us to take a deeper look into the intrinsic 
complexity of the brain at the nanoscale. Our outdated static view of the brain is no longer 
applicable, and we only begin our journey of uncovering the dynamic image of the brain, a 
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collection of billions of dynamic interneuron connections that are subject to active 
remodeling due to internal and external inputs. The recently announced Brain Activity 
Mapping (BAM) project seeks to apply novel, high-resolution, nanoscale approaches to 
advance our understanding of the complexity of neural circuits.1-4 Since 2002, the mission of 
our lab has been just that – the development of targeted molecular probes based on 
semiconductor nanocrystals to aid in the quest of elucidating molecular mechanisms 
underlying mental illness and discovering novel, more effective therapeutics. We have 
focused our research efforts on the family of integral membrane monoamine transporters 
(serotonin transporter, SERT; dopamine transporter, DAT; norepinephrine transporter, 
NET). To date, we have been pursuing the following goals: (i) synthesis of small-molecule 
organic ligands that allow non-invasive recognition of monoamine transporters at the surface 
of live cells, (ii) single-molecule investigation of the role of membrane dynamic nanoscale 
compartmentalization and dysregulated protein-protein interactions in the onset and 
progression of mental illness, particularly major depression and attention 
deficit/hyperactivity disorder, and (iii) development and validation of fluorescence-based 
drug discovery assays that may aid in high-throughput screening of antidepressant and 
antipsychotic drug candidates. My own efforts have revolved around the dopamine 
transporter protein, which has been implicated in psychostimulant abuse, clinical depression, 
attention deficit/hyperactivity disorder, and Parkinson’s disease, and culminated in the 
development of dopamine transporter-specific, fluorescence-based, high-resolution labeling 
protocol (Chapter IV), validation of flow cytometry-based, high-content screening assay 
aimed at discovery of novel dopamine transporter modulators (Chapter V), and single-
particle visualization of cell surface dopamine transporters as well as investigation of 
molecular mechanisms controlling dopamine transporter membrane dynamics (Chapter VI). 
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I open this dissertation with a thorough overview of the chemical/photophysical properties 
of semiconductor nanocrystals and their utility in biological research (Chapter II) and a 
collection of ensemble and single-particle labeling protocols that I have developed and 
validated over the past few years (Chapter III). I will close with a brief summary of my 
research accomplishments and offer a glimpse into the future research topics that will be 
tackled in the Rosenthal lab (Chapter VII).  
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CHAPTER II 
 
BIOLOGICAL APPLICATIONS OF PHOTOLUMINESCENT 
SEMICONDUCTOR QUANTUM DOTS. 
 
2.1. Introduction 
Recent advances in photoluminescence-based techniques for molecular biology have 
allowed investigators to study fundamental biological processes in living systems with 
unprecedented spatiotemporal resolution in real time. The dynamic nature of biological 
processes in conjunction with instrumentation progress demanded that new classes of 
improved probes be developed to allow access to spatial and temporal scales that have 
largely remained undisturbed by scientific inquiry with conventional biochemical means.1-5 
Currently, there are several classes of photoluminescent probes available to biologists 
including, but not limited to, small organic dyes5,6, genetically encoded fluorescent proteins7,8, 
metal-ligand complexes9,10, silver
11,12, carbon13,14, and silicon15 nanoparticles, and 
semiconductor nanocrystals16-21, termed as quantum dots (QDs). Among these, QDs have 
already proven to be valuable tools in biological inquiry since their introduction to the field 
in 1998.18,19 
QDs are nanometer-sized semiconductor nanocrystals with the exciton Bohr radius 
on the order of or smaller than that of the bulk semiconductor material.22 The quantum 
confinement effects lead to the increase of band gap and the appearance of discrete energy 
states, and together with the robust inorganic nature of the QDs give rise to their unique 
photophysical properties.22 QDs are characterized by excellent brightness that is a product of 
large molar absorption coefficients, typically ranging between 100,000-1,000,000 M-1cm-1 at 
the first excitonic absorption band, and high photoluminescence (PL) quantum yields (QYs), 
with values reported close to unity for CdSe/CdZnS nanocrystals emitting in the visible 
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range (400-700 nm).16,23-25 They have broad absorption spectra that gradually decrease 
towards longer wavelengths and narrow, Gaussian, emission spectra independent of 
excitation wavelength. The full width at half maximum (FWHM) of the emission spectra are 
~ 25-40 nm in the case of CdS, CdSe, CdTe QDs and slightly higher values of ~70-90 nm 
for PbS and PbSe QDs.26,29 The position of the emission peak is size-dependent and shifts to 
longer wavelengths as the QD size increases. Size tunability of the emission spectra 
combined with broad absorption spectra enables and considerably simplifies multiplexing, 
simultaneous imaging of several fluorophores using a single excitation source.30-33 The robust 
inorganic nature of QDs and effective surface passivation strategies render them resistant to 
photodegradation under continuous illumination and physiological conditions.29,31 Long-term 
dynamic imaging at high frame rates fully takes advantage of their excellent photostability. 
PL lifetime of QDs (>10 ns) is significantly longer than conventional organic dyes lifetimes 
(1-4 ns).6,34 Time-gated imaging and fluorescence lifetime imaging microscopy (FLIM) 
techniques exploit such lifetime differences to achieve higher contrast and signal-to-noise 
ratio (SNR).35-37 However, the complicated multi-exponential fluorescence decay behavior of 
QDs and significant variations of QD spectral properties within a single batch are intrinsic 
limitations for fluorescence lifetime-based imaging techniques.34,38 Also, with the two-photon 
absorption cross sections larger than those of any other photoluminescent probe, QDs are 
an attractive choice for multiphoton in vivo imaging applications.39 Overall, it is the ability to 
tune QD photophysical properties through synthetic control and surface modification that 
makes them an exciting class of photoluminescent probes for biological applications. 
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2.2. Quantum Dot Material Composition 
The peak emission wavelength of QDs depends on the material composition in addition to 
nanocrystal size and the degree of dispersity. Therefore, it is possible to obtain desirable QD 
optical properties for a given biological application by varying the material constituents of 
the semiconductor nanocrystal. Cadmium selenide (CdSe) is the most commonly used 
material for QD preparation. CdSe-based QDs are characterized by high quantum yields and 
effectively span the entire visible light range (420-660 nm).24,26,29,40-42 Other QDs include CdS 
(II/VI type) that feature blue-shifted peak emission wavelengths extending into the near-
ultraviolet region (350-400 nm) and CdTe (II/IV type) that allow biological investigation in 
the far-red and near-infrared (NIR) spectrum regions (660-750 nm).29,43-46 III/V and I-IV-VI2 
QDs such as InP, ternary InxGa1-xP, and CuInS2/ZnS have been prepared in attempt to 
develop more environmentally friendly alternatives to Cd-based semiconductor 
nanocrystals.47-52 Also, syntheses of NIR-emitting PbS and PbSe QDs (≥700 nm) have been 
reported.26,27 NIR QD probes offer a promising potential in deep tissue and in vivo imaging 
by dramatically improving tissue penetration depth and minimizing cellular damage from the 
excitation source.  
All of the QD materials mentioned above suffer from low quantum yield and poor 
thermal and photochemical stability under physiologically relevant conditions if not properly 
surface-passivated. Encapsulation of a core particle in a shell of wider-bandgap 
semiconductor material significantly improves QD PL QY and stability by eliminating the 
presence of reactive surface trap states that induce unfavorable non-radiative relaxation 
processes and physical degradation.26,40-42 A one- or two-layer inorganic shell was shown to 
increase photoluminescence quantum yield by up to 300%.40 As the thickness of the 
inorganic shell increases, the core particle exhibits higher resistance to degradation. In the 
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case of CdSe cores, CdS/ZnS is the surface-passivating material of choice to give 
CdSe/CdZnS core/shell QDs a reported photoluminescence quantum yield in excess of 
85%.23   
 
2.3 Quantum Dot Solubilization Strategies 
QDs must satisfy several requirements to be compatible with biological systems. 
They must be rendered water-soluble and stable in physiologically relevant pH and ionic 
strength ranges, possess functional surface elements that confer biological specificity, display 
minimal nonspecific interactions, and retain their optical properties after post-preparative 
surface modifications. Since core/shell semiconductor nanocrystal synthesis typically takes 
place in high-temperature, organic, nonpolar solvents, the as-prepared nanocrystals have no 
intrinsic water solubility due to the hydrophobic nature of the organic capping ligands 
(trioctylphosphine oxide, TOPO; hexadecylamine, HDA).29,42 Currently, the main 
approaches to rendering as-prepared QDs water-soluble are (i) ligand cap exchange, (ii) 
encapsulation in a heterobifunctional polymer shell, and (iii) encapsulation in a silica shell. In 
the ligand cap exchange (LCE) approach, bifunctional ligands, which contain a point of 
attachment to the core/shell nanocrystal surface and a hydrophilic moiety to aid in aqueous 
dispersion, displace native organic capping ligands. Surface attachment of the ligand occurs 
via a thiol (-SH), amine (-NH2), or phosphine (-PH2) functionality, and such groups as 
hydroxyl (-OH), carboxyl (-COOH), methoxy (-OCH3), and polyethylene glycol [(-
OCH2CH2-)n] provide the hydrophilic interface that is necessary to render QD water-soluble. 
Representative examples of the ligands used in LCE approach are demonstrated in Figure 
2.1. Thiolated carboxylic acids are commonly chosen as the capping ligands due to the 
 8 
 
strong binding affinity of thiols to the QD surface metal atoms.20 In the case of the polymer 
 
Figure 2.1. List of ligands used in the ligand cap exchange solubilization approach. 
 
encapsulation approach, native TOPO/HDA are retained and associate with added 
amphiphillic polymer via hydrophobic interactions.53-55 The aliphatic chains of TOPO/HDA  
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protrude into the surrounding environment and tightly interdigitate with the aliphatic chains 
of the added amphiphillic polymer, phospholipid, or amphiphillic polysaccharide through 
hydrophobic interactions (Figure 2.2). The outer hydrophillic backbone of the resulting 
polymer shell aids in the aqueous dispersity and colloidal stability of the encapsulated QD 
water-soluble and presents functionalities necessary for further conjugation (e.g., -COOH). 
Figure 2.2. List of polymers used in the polymer encapsulation approach. 
 10 
 
In the silica encapsulation approach, as-prepared core/shell nanocrystals are coated with an 
inert silica shell via techniques based on the adapted Stöber method or the water-in-oil 
reverse microemulsion method.56-63 The Stöber method is based on the alkaline hydrolysis 
and condensation of tetraethyl orthosilicate (TEOS) in ethanol:water mixtures and involves 
surface exchange of the native QD capping ligands with a silane coupling agent such as 3-
mercapto-1-propane sulfonic acid (MPS). In the microemulsion approach QDs do not act as 
seeds for silica growth but are instead incorporated into silica spheres formed by the 
hydrolysis and condensation of TEOS at the water/oil interface. 
Each of the QD solubilization approaches mentioned above is associated with 
distinct advantages and drawbacks and may be chosen depending on the requirements a 
particular biological system imposes on the photoluminescent probe. Ligand-exchanged 
QDs are known to suffer from significant quantum yield loss and poor long-term colloidal 
stability in aqueous buffers due to the surface-altering nature of the ligand-exchange process 
and the dynamic character of QD-ligand bonds.20 QD stability may be improved through the 
use of polydentate ligands with multiple attachment sites to the nanocrystal surface. For 
example, dihydrolipoic acid (DHLA) and oligomeric phosphines were reported to 
dramatically prolong the shelf life of QDs in comparison to monodentate thiol ligands.64,65 In 
addition, the lack of tools to determine the efficiency of the LCE process and the final 
surface coverage remains a significant obstacle to broader use of ligand-exchanged QDs in 
biological applications.20 Amphiphillic polymer encapsulation has thus far been the preferred 
solubilization strategy since polymer-coated QDs retain the native passivating ligands and do 
not exhibit significant loss of photoluminescence quantum yield. In addition, the use of an 
amphiphillic polymer shell results in excellent QD stability over a wide range of pH and 
aqueous buffer concentrations.66 Similar to the polymer shell, silica shell provides QDs with 
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improved colloidal stability and preserves QD optical properties. However, in contrast to 
LCE approach, a silica shell and polymer encapsulation significantly increase hydrodynamic 
diameter (HD) of QDs, with typical HD values of 30-40 nm.53,66 Increased post-
encapsulation QD size places limits on the applicability of QDs to size-sensitive biological 
applications such as single-QD tracking (SQT), intracellular delivery, and fluorescence 
resonance energy transfer (FRET). 
An alternative approach to prepare water-soluble QDs is synthesis directly in 
aqueous medium .67-69 This allows avoiding any post-preparative solubilization modifications 
and possibly eliminating large decreases in QY associated with such processing. There have 
been a few reports of aqueous preparations of QDs capped with 3-mercaptoethanol, 
thioglycerol, thioglycolic acid (TGA), and glutathione.69,70 Although a water-based approach 
is simpler and cost-effective in comparison to the traditional TOPO synthetic methodology, 
QDs prepared in water tend to suffer from lower quantum yields and broad emission 
spectra, which severely limits their utility in biology.  
 
2.4. Quantum Dot Functionalization Strategies 
QDs must be rendered water-soluble in such a way that they contain or allow 
subsequent conjugation of functional surface elements, which enable specific recognition of 
biological targets. In addition, it is desirable to obtain QD conjugates that display minimal 
nonspecific interaction with the surrounding biological environment. Several methodologies 
have been developed to confer biological specificity to QDs and can be grouped into 
covalent conjugation and noncovalent interaction strategies (Figure 2.3).  
In covalent conjugation strategy, a reactive group (-COOH, -NH2, -SH) at the QD 
surface is coupled to a biomolecule containing a compatible reactive group with the use of a  
 12 
 
 
 
cross-linker molecule. Coupling agents such as 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
(SMCC) are commonly used to conjugate –COOH and –NH2 groups and –NH2 and –SH 
groups respectively (Figure 2.3:A,B). Such covalent conjugation methodology has been 
employed to couple a variety of biomolecules to QDs including proteins, peptides, nucleic 
acids, and small molecules (Figure 2.4). Also, direct attachment of biologically active 
molecules to the QD surface during ligand exchange may also be used to impart QDs with 
Figure 2.3. QD functionalization strategies. EDC/SMCC covalent conjugation strategies 
are shown in A and B. Electrostatic assembly of MBP protein on DHLA-capped QDs is 
shown in C.64 Conjguation of streptavidin-conjugated QDs to biotinylated antibody to give 
an immunofluorescent probe is shown in D. 
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biological specificity. For example, Pinaud et al. coated CdSe/ZnS core/shell QDs with 
synthetic phytochelatin-related α peptides that contained a cysteine-rich adhesive domain for 
direct conjugation to QD surface Zn atoms.71 Gomez et al. used a combination of 
mercaptopropionic acid and thiolated RGD peptide to modify the surface of CdS QDs and 
subsequently target αvβ3 integrin receptors in rat neuroblastoma PC12 and rat neonatal 
cortical cells.72 In another example, Mitchell and colleagues used alkylthiol-capped 
oligonucleotides to functionalize CdSe/ZnS core/shell nanocrystals and study their 
interactions with complementary Au-DNA hybrids.73 
 
 
Among all the classes of biomolecules successfully conjugated to QDs, polyethylene 
glycol (PEG) and tetrameric protein streptavidin (Sav) deserve a special mention. PEG is a 
water-soluble, flexible, organic polymer and is generally considered to be chemically inert 
and have low toxicity.74 Due to their excellent biocompatibility, PEG groups were utilized to 
address the issue of nonspecific binding to the surrounding environment reported for QDs, 
especially those functionalized with carboxylic acid groups. Bentzen et al. conjugated PEG 
chains with average molecular weight of 2000 Da to amphiphillic polyacrylic acid-coated 
Figure 2.4. Biomolecules covalently conjugated to the QD surface via 
EDC/SMCC methodology. 
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QDs functionalized with carboxylic acid groups (AMP-QDs).75 PEG surface modification 
significantly reduced nonspecific interactions of AMP-QDs with different cell lines used in 
the study. In another study, Chattopadhyay et al. observed that PEGylated QDs effectively 
address the issue of poor separation of dimly and brightly staining cell populations in flow 
cytometry.33 Also, passivation with PEG was reported to minimize nonspecific complexation 
of bovine serum albumin (BSA) with QDs.76 Currently, surface passivation with PEG has 
been employed in a large variety of QD architectures including QDs commercially available 
from Invitrogen® (Carlsbad, CA).  
In 2002, Goldman et al. prepared avidin-conjugated QDs and used them in 
fluoroimmunoassays in conjunction with antibodies chemically tagged with biotin 
(biotinylation), a small organic molecule with a high affinity for avidin.77 The authors 
emphasized the general utility and large potential of such mixed covalent conjugation 
approach whereby avidin is used as a bridge between inorganic semiconductor fluorophores 
and biotinylated probes. Streptavidin is a homotetrameric protein with a molecular mass of 
~52.8 kDa.78 Each streptavidin tetramer is capable of binding four biotins, and streptavidin-
biotin interaction is one of the strongest and most stable noncovalent interactions known in 
nature (disscociation constant, KD ~ 10-15 M; half-life, greater than several days).79 
Glycosylated, positively charged avidin and deglycosylated neutravidin are similar, 
evolutionary unrelated biotin-binding proteins that may be used instead of streptavidin.80 
Due to excellent stability, tight interaction, and minimal nonspecific binding, streptavidin-
biotin assembly has become a very popular basis for QD biological targeting approach. In 
2002, Wu et al. targeted the breast cancer marker Her2 with the QD-streptavidin (QD-strep) 
conjugates together with humanized anti-Her2 antibody and biotinylated goat anti-human 
IgG.81 They also used the multicolored QD-streptavidin conjugates to visualize actin 
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filaments, microtubules, and nuclear antigens in 3T3 mouse fibroblast cells. In both cases, 
little to no nonspecific binding was observed when the streptavidin-conjugated QDs were 
incubated with the cells only. Dahan et al. used the QD-strep conjugates to investigate the 
diffusion dynamics of individual glycine receptors (GlyR) in the neuronal plasma membrane 
in a single QD tracking (SQT) experiment.82 Again, specific labeling was achieved through 
the use of a QD-strep conjugate, a biotinylated secondary antibody (Fab fragment),and a 
GlyR-specific primary antibody. In another example, Lidke et al. relied on biotinylated 
epidermal growth factor (EGF) and the QD-strep conjugates to elucidate a previously 
unreported mechanism of retrograde transport to the cell body of the erbB1 receptor 
tyrosine kinase.83  
Although biotinylated antibodies are frequently used in conjunction with QD-strep 
conjugates for immunofluorescent staining, there are several drawbacks associated with the 
antibody-based labeling strategy (Figure 2.3 D; Figure 2.5 A).84,85 In particular, the final size 
of the QD-antibody conjugate is large (~50 nm) compared to the labeling target, and the 
antibody-target interaction often suffers from poor stability. It should also be noted that the 
generation of an efficient antibody against the extracellular epitope of the biological target of 
interest is typically a costly and complicated procedure that does not ensure a high-affinity 
final product. In an attempt to address the weaknesses of the antibody-based labeling, 
Howarth et al. developed a direct, enzymatic, site-specific cell surface protein targeting 
strategy.86 In this strategy, a fifteen amino acid acceptor peptide sequence (AP) is genetically 
fused to either C- or N-terminus of the protein, and biotin ligase (BirA) is used to biotinylate 
a lysine side chain within the AP sequence. The attached biotin then serves as a handle for 
streptavidin-conjugated QDs. Such strategy was employed by Howarth et al. to label α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors in neurons and 
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subsequently observe plasma membrane trafficking of the AMPA-QD complex in the 
crowded synaptic cleft. In a more recent example, Sun et al. utilized BirA to biotinylate 
calmodulin subunits of myosin X molecular motor and subsequently visualized the 
movement of myosin X along actin filaments and bundles with QD-strep conjugates.87 
Alternative specific targeting approaches have recently emerged and are based on the 
expression of high-affinity fusion tags (CrAsH, Halotag, polyhistidine) by the cellular 
target.88-91 QDs are directed to the target by conjugation with the complementary fusion tag-
recognition elements. Our group relies on conjugation of small-molecule ligands to confer 
biological specificity to QDs.85-92 In 2002, we conjugated serotonin (5-HT), a monoamine 
neurotransmitter, to CdSe/ZnS core/shell nanocrystals and measured the 
electrophysiological response of the interactions between QD-5-HT conjugates and 5-HT3 
receptor (Figure 2.5 B). Also, we utilized the QD conjugates to visualize human serotonin 
transporter protein (hSERT) transiently expressed in human embryonic kidney (HEK) cells. 
The small-molecule strategy is a cost-effective alternative to antibody-based 
immunofluorescent labeling that results in significantly smaller final QD size. However, one 
must ensure that the site of attachment on the small molecule does not alter its biological 
function.  
Biological specificity can also be introduced to QDs via adsorption and electrostatic 
self-assembly in addition to covalent coupling. Mattoussi et al. constructed two-domain 
maltose-binding protein-basic leucine zipper (MBP-zp) fusion protein and conjugated it to 
dihydrolipoic acid (DHLA)-capped CdSe/ZnS core/shells (Figure 2.3 D).64 The MBP-zp 
fusion protein self-assembled on the surface of DHLA-capped QDs through electrostatic 
interactions between negatively charged DHLA carboxyl groups and positively charged 
leucine zippers of the MBP-zp fusion protein. Goldman et al. used the highly basic leucine 
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zipper domain as the basis for the engineered molecular adaptor PG-zb protein, which 
served as a bridge for subsequent conjugation of IgG antibody to DHLA-capped CdSe/ZnS 
core/shell nanocrystals.93 In the report by Hanaki et al., a series of ten serum albumins were 
nonspecifically adsorbed on the surface of CdSe/ZnS core/shells coated with 11-
mercaptoundecanoic acid (MUA).94 QDs complexed with sheep serum albumin (SSA) were 
found to be the most stable in aqueous solution.  
To sum up, there exist several surface modification strategies that render QDs water-
soluble and biocompatible. Each strategy is associated with distinct advantages and 
disadvantages. Therefore, the surface modification approach must be carefully chosen as it 
determines photophysical properties of solubilized and functionalized QDs and ultimately 
the outcome of the experiment. In addition, rigorous control experiments must be 
performed to determine whether the biological activity of the molecule conjugated to QDs is 
retained.  
 
2.5. Quantum Dot Biological Applications: Cellular Labeling 
Fluorescent labeling of extra- and intracellular components is the area in which QDs excel. 
Their high brightness ensures cellular component visualization with high signal-to-noise ratio 
(SNR) and eliminates the need for a large number of fluorophores to produce a pronounced 
signal.95  As a consequence, QDs have been successfully used to label a tremendous number 
of cellular components both external and internal to the plasma membrane in various types 
of fixed and live cells (Figure 2.5 A,B; Table 2.1). Their excellent resistance to degradation 
and photobleaching in physiologically relevant conditions enables microscopy image 
acquisition for extended periods of time under constant illumination  
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without significant image quality loss. Such superior photostability has been often referred to 
as the most impressive feature of QDs. Indeed, it opens the door to individual protein, 
endosome, virus, or whole cell long-term dynamic tracking experiments with unprecedented 
three-dimensional spatial and temporal resolution. The ability to visualize and analyze the 
dynamic interactions between viruses and host cells was recently demonstrated by Joo et al. 
who tagged human immunodeficiency virus (HIV) with QD-strep conjugates via site-specific 
BirA biotinylation and examined the kinetics of QD-HIV complex internalization into 
mammalian cells.96 Single virus tracking experiments offer an opportunity to visualize and 
elucidate the molecular details of the viral infection process. In the case of whole cell 
tracking, QDs may be used to monitor transplanted and stem cell location, survival, and 
differentiation. For example, Schormann et al. attempted to track and examine metastatic 
behavior of QD-tagged MCF-7 human breast cancer cells transplanted into healthy mice. 
Tracking studies at the single QD level will be described in detail in the SQT section.97 
Figure 2.5. Quantum dots in cellular and whole animal in vivo imaging. 
Immunofluorescent labeling of extracellular Her2 cancer marker with antibody-conjugated 
QDs is shown in A. Reprinted from reference 81 by permission from MacMillan Publishers 
Ltd:Nature Biotechnology, copyright 2003. Visualization of hSERT in HEK-293T cells with 
serotonin-conjugated CdSe/ZnS core/shell nanocrystals is shown in B. Reprinted with 
permission from reference 92. Copyright 2002, American Chemical Society. The use of QDs 
to target cancer tumors in living mice is shown in C. Reprinted from reference 55 by 
permission from MacMillan Publishers Ltd:Nature Biotechnology, copyright 2004. 
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 In contrast to conventional photoluminescent probes, QDs are ideal candidates for 
multiplexing labeling experiments owing to their broad absorption spectra and size-tunable, 
narrow, Gaussian emission spectra. They effectively eliminate the need for multiple 
excitation sources and convoluted spectral compensation algorithms. In 2007,  
 
Chattopadhyay et al. were able to resolve seventeen fluorescence emissions including eight 
QD emissions in a polychromatic flow cytometry experiment, the most impressive 
Table 2.1. Intracellular and extracellular components labeled with QDs. 
Table 1.1. Intracellular and extracellular components labeled with QDs. 
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demonstration of QD multiplexing abilities to date.33 In this study, nine antibody-conjugated 
organic dyes and eight pMHCI antigen- and antibody-conjugated QDs were featured in a 
seventeen-color staining panel to immunophenotype antigen-specific T cells. The resolution 
of the eight QD emissions was achieved with minimal spectral compensation requirements.  
 
2.6. Quantum Dot Biological Applications: Single-QD Tracking 
SQT has emerged as a powerful technique to investigate individual dynamics rather 
than an ensemble average behavior of QD-tagged single molecules. Careful analysis of SQT 
data allows elucidation of the molecular details of various biological processes, in particular 
membrane trafficking of cell surface proteins.95 The visualization and interpretation of the 
dynamic interaction with the biological surroundings have been reported for QD-labeled 
growth factors, cell surface receptors, membrane lipids, molecular motors, and synaptic 
vesicles. In a typical SQT experiment, one must label the biological target of interest with a 
QD, introduce a biological stimulus, observe the effect via image time-series acquisition, 
apply an algorithm to identify and locate single QD positions in each frame, link QD 
positions in successive frames to generate trajectories, and analyze the obtained trajectories 
(Figure 2.6). The x-y position of the diffraction-limited QD spot can be located by two-
dimensional Gaussian fitting of its point spread function (PSF) via fluorescence imaging with 
one nanometer accuracy (the FIONA technique).988 The localization accuracy is dependent 
upon the standard deviation of the PSF and the number of photons detected from a single 
QD. Very bright particles like QDs significantly improve SNR image profile and can be 
located with high accuracy (as low as ~10 nm for a single QD).95 The next step is to link the 
centers of single QD spots across adjacent frames of the entire image time-series to generate 
QD trajectories. The overwhelming majority of studies so far focused on particle dynamics  
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in an XY coordinate system. However, it will not be long before three-dimensional (3D) 
SQT will become the norm, with the emergence of 3D tracking techniques.99-101 There are 
several tracking software packages available online that can be used as a starting point to 
develop a QD tracking algorithm and obtain individual trajectories.  
When the tracking portion of the SQT experiment is completed, generated 
trajectories are analyzed to extract information about the QD dynamic behavior including 
displacement, velocity, and diffusion coefficient. Generally, QD mean-square displacement 
Figure 2.6. Scheme of data processing and analysis in the SQT experiment. 
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(MSD) is calculated as a function of time to reduce the noise of the experimental 
trajectory.102 The resulting MSD curve is used to determine whether the QD-tagged 
biological target undergoes Brownian, directed, confined, or anomalous diffusive behavior.103 
The extracted mode of motion parameters are subjected to rigorous statistical analysis and 
subsequent biological interpretation. Several examples that clearly demonstrate the utility of 
SQT for elucidating the molecular mechanisms underlying the dynamic behavior of QD-
tagged biological structures are described below.  
In 2007, Cui et al. observed unidirectional retrograde transport of endosomes, 
containing QDs conjugated to nerve growth factor (NGF) dimer, along the neuronal axon 
(Figure 2.7 A).104 The QD-NGF complexes were internalized by endosomes at the distal 
axon in a 1:1 stoichiometry and subsequently transported to the cell body in a characteristic 
stop-and-go movement pattern. In 2009, Zhang et al. published a controversial report on the 
mechanism of presynaptic neuronal transmission in which they subjected single QD-loaded 
individual synaptic vesicles to external stimulus and then observed vesicular response.105 As a 
result, it was established that the transient vesicular fusion and reuse (kiss-and-run) is the 
preferred mechanism for presynaptic transmission as opposed to the full-collapse vesicular 
fusion. SQT is a particularly useful technique for elucidating dynamics of cell surface-
associated proteins such as potassium and CFTR channels, GABA, NMDA, Gly, and 
AMPA neurotransmitter receptors, and integrins.95 In a specific example, Heine et al. 
showed that postsynaptic AMPA glutamate receptors (AMPAR) undergo fast lateral 
diffusion (>0.25 µm2/s) which permits efficient replacement of desensitized receptors with 
the new, functional ones.106 Such AMPAR exchange facilitates rapid recovery of the 
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depressed synaptic transmission that can be slowed down by constraining the movement of 
 
Figure 2.7. Single-quantum dot tracking (SQT) examples. A. Cui et al. observed 
unidirectional retrograde transport of endosomes, containing QDs conjugated to nerve 
growth factor (NGF) dimer, along the neuronal axon. Reprinted from reference 104 by 
permission from PNAS, copyright 2007. B. Sun et al. visualized the movement of 
biotinylated myosin X along actin filaments and bundles with QD-streptavidin conjugates. 
Reprinted from reference 87 by permission from MacMillan Publishers Ltd:Nature 
Structural and Molecular Biology, copyright 2010. 
 
AMPAR within the synapse. Clearly, SQT allows detailed investigation of the aspects of 
neurotransmission with unprecedented spatial and temporal resolution.  
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In another remarkable display of their utility to the field of single-particle tracking, 
QDs were used to reveal the details of intracellular movement of kinesin and myosin motor 
proteins along cytoskeletal microtubules and actin filaments respectively. In particular, 
Pierobon et al. visualized and determined the size of individual steps myosin V takes in the 
hand-over-hand walking motion along the cytoplasmic actin filaments in living HeLa cells.107 
To observe this phenomenon, Myosin-QD constructs were loaded into the cytoplasm of live 
HeLa cells via nonspecific endocytosis technique and imaged with a wide-field epi-
fluorescence microscope (Figure 2.7 B). Molecular motor tracking experiments clearly 
demonstrated that QDs offer a promising potential in reporting intracellular dynamic activity 
of endogenous molecules. Existing strategies for intracellular delivery of QDs will be 
discussed in the following section.  
 
2.7. Quantum Dot Biological Applications: Intracellular Delivery and Therapeutics 
Successful use of QDs to probe membrane dynamics of extracellular proteins and 
intracellular motion of individual molecular motors in the cytoplasm of live cells leaves no 
doubt that QDs have a large potential to become intracellular activity photoluminescent 
reporters of choice. In addition to intracellular SQT and imaging various disease markers, 
QDs may be utilized as drug delivery vehicles or tags of conventional drug carriers. For 
example, Manabe et al. studied the effects of QD-conjugated captopril, an antihypertensive 
drug, on the blood pressure of hypertensive rats. QD-captopril conjugates and captopril 
alone were reported to decrease rat blood pressure to similar degree 30 min after 
administration.108 However, the hypotensive effect of the conjugates disappeared after the 
initial 60-min window. Additional experiments are required to shed light on the mechanism 
of therapeutic action of QD-conjugates. Recently, Bagalkot et al.demonstrated parallel 
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combination disease marker- and drug release-sensing elements in QD architecture. QDs 
were covalently conjugated with RNA aptamers (A10) which contained an intercalated 
chemotherapeutic agent doxorubicin.109 The A10 RNA aptamer enabled specific targeting of 
prostate specific membrane antigen (PSMA), while RNA-associated doxorubicin quenched 
fluorescence. Restored QD fluorescence due to the slow release of doxorubicin in the 
intracellular environment provided the means to monitor the therapeutic process in real 
time. Treatment of PSMA-positive cells with the QD-RNA-doxorubicin conjugates induced 
apoptosis and resulted in significant decrease of cell viability. In another instance, small 
interfering RNA (siRNA) molecules were covalently linked to the QD surface in an attempt 
to silence eGFP protein expression.73 QDs may also be used to visualize drug delivery via 
other drug carriers as demonstrated by Jia et al. They used QDs to visualize intracellular 
delivery of polyethyleneimine (PEI)-coated carbon nanotubes that served as a vector for an 
antisense oligodeoxynucleotide sequence, a hydrophilic therapeutic agent.110 
The future of intracellular applications of QDs depends on the efficient cytoplasmic 
delivery. Delehanty et al. group QD intracellular delivery strategies into three broad 
categories: (i) passive delivery, (ii) facilitated delivery, and (iii) active delivery.111 In passive 
delivery, hydrophilic QDs undergo nonspecific endosomal sequestration due to electostatic 
QD-membrane interactions. Jaiswal et al. visualized nonspecific endocytosis that occurred 
when HeLa cells were incubated with ~500 nM DHLA-coated QDs for several hours.112 
Although passive delivery is attractive in terms of simplicity, the cell type-independent 
internalization and the inability to escape endosomal sequestration remain significant 
challenges.  
Facilitated delivery is based upon QD functionalization with peptides, proteins, small 
molecules, lipids, and polymers. Typically, intracellular delivery is achieved through the initial 
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interaction of the QD conjugate with a specific receptor and the subsequent QD-receptor 
complex endosomal sequestration. Alternatively, QD conjugates undergo endocytosis due to 
electrostatic interactions between charged surface groups and plasma membrane. The 
positively charged TAT peptide and the arginine-glycine-aspartate (RGD) tripeptide are two 
prominent examples of peptides that mediate intracellular delivery of QDs. High positive 
charge of the TAT peptide due to the presence of a linear polyarginine (lysine) chain permits 
electrostatic interaction with negatively charged receptors and subsequent receptor-mediated 
endocytosis.113 On the other hand, the RGD peptide was reported to mediate QD delivery 
via binding to the membrane receptors known as integrins.114,115 Similarly to peptide-QD 
conjugates, protein- and small molecule-QD conjugates take advantage of receptor 
endocytosis, with QD specificity for a given cell membrane marker introduced by protein 
(small molecule). Antibodies, cholera toxin B, transferrin, and folate conjugated to QDs have 
all been reported to undergo endocytosis after binding to the corresponding cell membrane 
proteins.19,47,111,116 
Lipids and polymers have also been used to deliver QDs into cells. Derfus et al. 
reported the internalization of the liposomes containing commercial transfection agent 
Lipofectamine 2000 self-assembled on the surface of negatively charged QDs.117 Several 
reports describe the use of phospholipid-based micelles engulfing QDs in the central 
pocket.111 Bruchez et al. anchored the endosomal-disrupting PEG-PEI copolymers on the 
QD surface and observed subsequent cytoplasmic release of the QD-conjugates.18 While 
lipid- and polymer-mediated delivery usually results in a higher degree of uptake, the 
relatively large size of the final QD conjugate and the inability to control QD concentration 
and loading efficiency are likely to prevent this strategy from wide utilization. 
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In contrast to passive and facilitated delivery, active delivery techniques such as 
electroporation and microinjection rely on the application of mechanical stress to the cell 
membrane. In the electroporation technique, a brief electric pulse applied to the membrane 
temporarily permeabilizes the lipid bilayer and results in the influx of QDs into the 
cytoplasm. The advantages of electroporation are that a large number of cells can be 
processed simultaneously in a relatively inexpensive procedure. However, the QDs tend to 
aggregate near the membrane entry, which is undesirable for intracellular reporting 
applications. Also, a strong electrical shock applied to the cell suspension may result in 
reduced cell viability. In the microinjection technique, cells are first visualized with a 
fluorescent microscope, and then a thin-glass tube is used to inject a QD solution either into 
the nucleus or the cytoplasm of the cell.119 While QDs are typically dispersed at the injection 
site and diminished cell mortality is reported, microinjection is associated with high cost and 
low potential for high throughput. However, both active delivery techniques enable one to 
escape endosomal sequestration that typically occurs in other strategies. 
Overall, it is evident the intracellular fate of QDs depends on the QD size, surface 
coating, ability to escape endosomal capture, and specific intracellular localization. Much 
progress remains to be made in the field of intracellular delivery of QDs as the existing 
strategies are largely inadequate to meet the requirements for efficient drug delivery and 
intracellular dynamics sensing.  
 
2.8. Quantum Dot Biological Applications: FRET-based Biosensing 
Förster or fluorescence resonance energy transfer (FRET) has emerged as a powerful 
technique for monitoring biological events at the nanometer scale (1-10 nm) including 
ligand-receptor binding, protein-protein interactions, and biomolecular conformational 
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changes.120,121 FRET-based applications require a short distance between donor (D) and 
acceptor (A) molecules and finite spectral overlap between the emission spectrum of D and 
the absorption spectrum of A. In their extensive review, Medintz and Mattoussi discuss the 
utility of QD photophysical properties to FRET-based biosensing applications.122 In 
particular, the size dependency of the QD emission profiles allows tuning the D-A spectral 
overlap and maximizing energy transfer efficiency. Another useful property of QDs is the 
ability to form multivalent constructs. This becomes useful when several A molecules are 
attached to one QD, thereby improving FRET signal. While broad absorption profiles of 
QDs allow multiplexing experiments and significantly improve SNR in the FRET 
experiment by reducing direct excitation contribution to the FRET signal, they render QDs 
ineffective acceptor fluorophores.122 Therefore, a typical QD-FRET configuration includes 
an organic dye molecule serving as the acceptor fluorophore. Another serious limitation 
associated with QD-based FRET is the QD size. The energy transfer efficiency has a 6th 
order dependence on the D-A separation distance and is defined as: 
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where kD-A is the rate of energy transfer between D and A, τD is the exciton radiative 
lifetime of D, R0 is the Förster radius, and r is the center-to-center separation distance 
between D and A. Surface modification and functionalization of QDs significantly increases 
the final conjugate size and results in large D-A separation distances leading to poor FRET 
rates and low energy transfer efficiency. Nevertheless, QD-dye FRET pairs have been 
successfully utilized by many groups to sense nucleic acid hybridization, detect presence of 
ions in solution, monitor enzyme activity, and assess competitive receptor binding kinetics. 
Several biosensing applications of QD-FRET are discussed below.  
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In the first example, Zhang and Johnson used QD-FRET to study an aspect of the 
HIV-1 virus replication.123 Specifically, they attempted to monitor sequence-driven 
interaction between the arginine-rich fragment of Rev, a HIV-1 regulatory protein, and the 
RNA-based Rev responsive element, RRE IIB RNA. The experimental setup included 
streptavidin-coated QDs conjugated with biotinylated RRE  and the Rev fragment labeled 
with the Cy5 dye. To monitor RRE-Rev interactions, QD PL was recorded as function of 
Rev peptide concentration, and significant QD quenching was reported with increasing 
peptide concentration. The disruptive effect of neomycin B presence on the RRE-Rev 
association translated into significantly lower FRET rates. Such a QD-FRET configuration 
may be used as a template for FRET-based drug discovery platform targeting viral 
replication. In the second example of DNA sensing, Gill et al. attempted to detect a Texas 
Red-labeled DNA sequence with a thiolated complementary DNA sequence conjugated to 
CdSe/ZnS core/shell nanocrystals.124 Measurements of QD PL quenching and Texas Red 
PL were used to detect the hybridization process between the labeled complementary DNA. 
When DNase I enzyme was added to the solution, QD PL partial recovery was observed as 
the result of DNA hybrid degradation and simultaneous Texas Red separation. 
By coupling a dye with the pH-sensitive absorption profile to QDs, it is possible to 
accurately monitor pH changes in real time. In the report by Snee et al., squaraine dye was 
covalently conjugated to polymer-encapsulated QDs, and the FRET interactions were 
measured as a function of the solution pH.125 As a result, the ratiometric dependence of the 
QD and dye emission peaks were revealed and demonstrated the utility of such QD-dye 
assembly. In another example, Medintz et al. were able to detect the presence of the maltose 
sugar in solution with positively charged maltose-binding proteins (MBP) self-assembled on 
the DHLA-capped QD surface.126 Cy3-labeled MBP was specifically prebound to maltose 
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analog β-cyclodextrin (BCD) tagged with Cy3.5 dark quencher prior to self-assembly. 
Excitation of the QD resulted in Cy3 FRET-excitation that was then fully quenched by the 
BCD-Cy3.5 complex. Addition of maltose to the solution resulted in the displacement of 
BCD-Cy3.5 complex, with Cy3 PL recovery measured in a dose-dependent manner. Thus, it 
is possible to develop QD-protein biosensors for FRET-based sensitive nutrient detection. 
One of the most exciting QD-FRET applications to date is the use of QDs in 
photodynamic therapy (PDT). PDT has emerged as a cancer therapeutic tool alternative to 
surgical treatment and is widely used as treatment for several types of cancer, in particular 
basal cell carcinoma. In a general PDT process, a photosensitizing agent (PS) is 
photoexcited, and its excitation energy is transferred to a proximal triplet oxygen molecule to 
generate singlet oxygen. Singlet oxygen belongs to the family of reactive oxygen species 
(ROS) that are able to induce apoptotic damage of the cells in the immediate vicinity of ROS 
generation. By coupling the PS molecules to QDs in the QD-FRET-enhanced PDT, singlet 
oxygen generation quantum yield can be significantly increased as a result of the excellent 
UV or IR energy-harvesting capability of QDs and subsequent FRET excitation of the 
PSs.127-129 In addition, it is possible to anchor several membrane cancer marker-specific 
antibodies and PSs to the QD surface to achieve specific targeting and imaging of cancer 
cells along with highly localized therapeutic action of PSs (Figure 2.8).127 In the most recent 
proof-of-concept experiment, Tsay et al. conjugated two PSs, Rose Bengal and chlorine e6, 
to CdSe/ZnS QDs, with lysine-terminated phytochelatin-related peptides serving as a rigid 
linker between the QD surface and the PS molecule.129 Singlet oxygen generation was 
achieved either by indirect FRET-based excitation (355 nm) or direct laser excitation of PSs 
on the QD surface (532 nm) and detected spectroscopically at 1270 nm by measuring 
oxygen phosphorescence at 1270 nm. Singlet oxygen quantum yields as high as 0.17 and 0.31  
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Figure 2.8. Achieving specific targeting in photodynamic therapy. A cancer cell is first 
exposed to a primary antibody that specifically binds to an extracellular cancer marker. Then 
the cancer cell is incubated with multivalent QDs conjugated to secondary antibody and 
photosensitizer molecule128 
 
were reported for QD-Rose Bengal conjugates and QD-chlorin e6 conjugates respectively. 
Interestingly, quantum yields from indirect excitation were much higher for QD-Rose 
Bengal complexes suggesting FRET is the primary mechanism of singlet oxygen generation. 
The opposite was true for QD-chlorin e6 complexes, indicating that FRET-based excitation 
of chlorine e6 was considerably lower. Further experiments are needed to pinpoint the basis 
for such differences between the QD-PS conjugates. 
Performing FRET at the single molecule level offers the ability to monitor individual 
molecular interactions with increased sensitivity and temporal resolution when compared to 
ensemble experiments. In a general solution-phase single QD FRET experiment, emission 
intensity bursts of the donor and acceptor molecules are measured after the defined focal 
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volume of the solution is excited through a high numerical aperture objective.130 Zhang et al. 
utilized a single QD-FRET biosensor for accurate and highly sensitive detection of DNA 
sequences in solution.131 The Cy5-labeled target DNA sequence was captured by 
hybridization with the biotinylated complementary DNA sequence introduced into the 
solution. The Cy5- and biotin-terminated DNA hybrid was then mixed with streptavidin-
conjugated QDs, and the resulting solution with QD-DNA complexes was delivered into a 
glass microcapillary to minimize the sample volume for FRET analysis. The sensing 
responsitivity of the QD-FRET DNA biosensor was determined to be several orders of 
magnitude higher than that of the dye-based molecular beacon.  
Once again, the unique photophysical properties make QDs an attractive choice for 
the FRET-based biosensing and therapeutics applications. Clearly, there are significant 
challenges associated with QD-FRET, specifically QD-acceptor separation distances and 
QD-acceptor association multivalency. Addressing these issues will ensure that QD-FRET 
continues to be actively explored in a biological setting. 
 
2.9. Quantum Dot Biological Applications: In Vivo Deep Tissue Imaging 
Until recently, in vivo deep tissue fluorescence imaging relied on conventional dyes 
and suffered from poor tissue penetration depth, low SNR intensity profiles, and short-lived 
fluorescence signal. QDs offer several distinct advantages to the field of deep tissue 
imaging.21,55 First, their high brightness and the ability to shift their peak emission 
wavelengths to the far red and near-infrared (NIR) regions of the EM spectrum result in 
dramatic reduction of cellular autofluorescence, significant improvement of the SNR 
intensity profiles and tissue penetration depth. Second, their excellent photostability enables 
longer circulation times in the endothelial system and allows long-term imaging without the 
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significant image quality loss. Third, their large two-photon absorption cross sections permit 
the use of low-energy NIR excitation sources minimizing tissue damage and improving SNR 
profiles. Fourth, QD-based in vivo deep tissue imaging is a safer, cost-effective alternative to 
radiation-based imaging modalities. So far, intravitally injected QDs have been successfully 
used to image blood vessels, detect cancer tumors, and map lymph nodes in live animals.  
In work by Smith J. D. et al., a series of QDs of varying sizes and surface coatings 
were intravitally injected into the chick chorioallantoic membrane (CAM) blood vessels, a 
model system developed for studying angiogenesis and blood vessel formtaion in vivo.132 
Visualization of the chick blood vessels with NIR-emitting QDs produced a stronger, more 
uniform signal and eliminated virtually all of the background fluorescence compared to 
FITC-dextran, a dye-based vasculature visualization agent. It should also be noted that 
multiple QD injections produced no deleterious effects on the development of the chick 
embryo. In a more recent example, Smith B. R. et al. covalently attached ~30-50 RGD 
peptides to NIR-emitting QDs and injected QD-RGD complexes into the tail vein of live 
mice.133 The authors exploited intravital microscopy to monitor QD-RGD binding to 
integrins αvβ3 within the tumor neovasculature in real time. Interestingly, only QD-RGD 
aggregates and no single QD-RGD complexes were observed to bind to the tumor 
neovasculature. Also, it was reported that QDs were cleared from the vasculature via 
reticuloendothelial system within 1.5 hours post-administration. In another study describing 
the utility of QDs to the field of angiography, Larson et al. administered water-soluble QDs 
into living mice via tail vein injection and were able to clearly visualize QD-containing 
vasculature at a skin depth of ~ 100 µm via two-photon (900 nm) excitation microscopy.39 
In 2004, Gao et al. described the use of amphiphilic triblock copolymer-encapsulated 
QDs to visualize human prostate cancer tumors in living nude mice (Figure 2.5 C).55 PEG 
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chains and PSMA-specific antibody were conjugated to polymer-coated QDs to achieve 
passive and active targeting of cancer cells respectively. QD complexes were administered 
into living animals via tail vein injection and were allowed a 24-hour circulation period for 
QD accumulation in the tumor. The acquired spectral fluorescence images of whole animals 
clearly demonstrated QD accumulation in the prostate cancer tumors. Nonspecific activity 
of QD-PSMA Ab conjugates was determined by histological examination of six different 
host organs, showing nonspecific QD uptake in the liver and the spleen. The rate of uptake 
and retention of QD-PEG conjugates was significantly lower and was attributed to small 
hydrodynamic diameter of the conjugate.  
Kim et al. utilized type II NIR-emitting (840-860 nm) QDs as surgical aids during 
the sentinel lymph node (SLN) mapping procedure in the mouse and pig (Figure 2.9).135 
After subcutaneous administration of 400 pmol of QDs on the thigh of the pig, it was 
possible to quickly localize the position of the SLN at the depth of ~ 1 cm in real time. The 
localization was achieved using a low fluence rate of 5 mW/cm2 of NIR excitation light. 
According to Kim et al., NIR QDs considerably simplify surgeon’s task of indentifying the 
SNL and performing complete resection during the cancer surgery. 
Despite multiple successful demonstrations of their use in vivo, QDs face significant 
challenges before they can be approved for clinical use. The large size of QD-conjugates 
promotes QD retention in the liver and the spleen and prevents renal clearance, which 
imposes a 5-6 nm maximum size requirement.135 In addition, toxicity remains a widely 
discussed issue and will be addressed in a separate section. 
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Figure 2.9. Sentinel lymph node mapping surgical procedure aided by NIR-emitting 
type II QDs. Reprinted from reference 134 by permission from MacMillan Publishers 
Ltd:Nature Biotechnology, copyright 2004. 
 
2.10. Quantum Dot Biological Applications: Multimodal Imaging 
Although QD-based fluorescence microscopy has demonstrated potential for in vivo 
molecular imaging, the tissue penetration depth is limited by the working distance of the 
microscope objective and excitation light scattering.136 However, it is possible to enhance the 
visualization of QDs in vivo by introducing an additional property, such as paramagnetism, 
which allows molecular imaging in multiple modes. Paramagnetic QDs can serve as both 
photoluminescent probes and magnetic resonance imaging (MRI) contrast agents in a highly 
complementary bimodal molecular imaging mode. Several paramagnetic QD architectures 
have been developed. Yi et al. reported the synthesis of silica-coated nanocomposites of 
magnetic nanoparticles and QDs.63 γ-Fe2O3 nanoparticles and CdSe QDs were prepared 
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separately and then encapsulated in a silica shell via reverse microemulsion. The resulting 
nanocomposites retained the paramagnetic properties of γ-Fe2O3 and the optical properties 
of CdSe. Mulder and colleagues prepared paramagnetic QDs by coating CdSe/ZnS 
core/shells with a phospholipid micelle composed of a pegylated phospholipid, PEG-DSPE, 
and a Gd-containing paramagnetic lipid, Gd-DTPA-BSA.137 Chelated complexes of Gd are 
widely used as MRI contrast agents. The paramagnetic QDs were then functionalized with 
integrin-specific RGD peptide and were used to image human umbilical vein endothelial 
cells. In another example, Yang et al. functionalized silica-coated Mn-doped CdS/ZnS 
core/shells with Gd via capture of GdIII ions by TSPETE, a metal-chelating silane.138 
Inductively coupled plasma (ICP) analysis was utilized to determine the average number of 
Gd III ions on the QD surface to be ~107. QD-Gd complexes possessed large proton 
relaxavities and retained yellow PL emission of the original QDs. In conclusion, the bimodal 
character of paramagnetic QDs makes them useful MRI contrast agents with the capability 
of parallel optical detection.  
 
2.11. Quantum Dot Toxicity Concerns 
QD core semiconductor constituents, such as Cd, Se, and Te, are highly toxic in their 
bulk form, and their adverse effects have been well documented. In particular, Cd exposure 
is associated with the increased rates of cancer, birth defects, and endocrine disruption.139 In 
addition, Cd is known to facilitate the formation of reactive oxygen species, causing 
subsequent oxidative damage. Recently, several reports presented evidence that Cd expresses 
genotoxic activities in mammalian cells and animals, specifically chromosomal damage and 
gene expression modulation.140 There is sufficient evidence establishing the toxic effects of 
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II-IV bulk semiconductors to raise concerns about possible deleterious impact of their 
nanoscale counterparts on the biological systems.  
Numerous reports on the cytotoxicity associated with the utilization of QDs in 
biological setting have been published to date. In his comprehensive review in 2006, 
Hardman et al. summarized the existing state of knowledge on in vivo toxicity and biological 
fate of QDs.135 Hardman concluded that QD toxicity ultimately depends on the effectiveness 
of the nanocrystal surface passivation, which directly influences QD size, charge, and 
stability. Indeed, several recently published toxicity studies have shown that QD toxicity can 
be minimized through complete suface passivation with an appropriate choice of inorganic 
shell or surface coating. In 2009, Pelley et al. published another extensive review, in which 
they updated, expanded and put Hardman’s 2006 review in a regulatory context.141 Particular 
attention was paid to biological and environmental fate of QDs and a striking lack of studies 
showing QD long-term effects. Currently, QD toxicity still remains a widely discussed issue 
with many questions remaining to be answered.  
Inherent toxicity of traditional QD core material constituents is a serious obstacle to 
the clinical utilization of QDs. To address this issue, III-V and I-III-VI2 materials have been 
employed to replace toxic II-IV semiconductor elements in the QD architecture. 
Unfortunately, new materials suffer from sub-par performance compared to their traditional 
counterparts, and there have not been any reports establishing their reduced toxicity until 
recently. 
 
2.12. Current Limitations of Quantum Dots 
QDs have undoubtedly demonstrated their utility to the field of biological 
investigation. However, there several distinct limitations associated with QDs that must be 
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overcome before QDs can become the routine biological photoluminescent probes of first 
choice. First, the final size of biocompatible, water-soluble, functionalized QD conjugates 
can easily exceed 20 nm in diameter and several hundred kDa in molecular mass.95,142 This is 
especially true in the case of polymer-encapsulated streptavidin-coated QDs conjugated to 
large biotinylated antibodies. The large size of QD probes may impair labeled protein 
trafficking in SQT, causes reduced FRET efficiency between donor and acceptor molecules, 
and restricts access to crowded cellular locations. In addition, large hydrodynamic diameter 
precludes QDs from being cleared from the body via renal filtration or urinary 
excretion.135,141 Current strategies to reduce QD size are aimed at the development of new 
compact surface encapsulants, shorter linkers, and conjugation strategies as well as the 
reduction of QD multivalency. 
Although multivalency has been successfully used in several instances to maximize 
the utility of QDs, it can cause QD aggregation due to cross-linking during conjugation and 
impair receptor mobility by cross-linking cell surface proteins. The ability to synthetically 
control QD valency will effectively eliminate issues due to cross-linking and significantly 
reduce the hydrodynamic diameter of QD conjugates. In an attempt to generate monovalent 
QDs, Howarth et al. conjugated single monovalent streptavidin (mSa) with a femtomolar 
biotin binding site to core/shells coated with DHLA-PEG8-COOH and used the QD-mSa 
conjugates to visualize membrane mobility of individual LDL receptors.143  
Single QD photoluminescence emission intensity alternates between dark and bright 
states, and such fluorescent intermittency has been referred to as blinking (Figure 2.10 A). 
Several models have been proposed to explain the mechanistic basis underlying the blinking 
phenomenon of single QDs.144,145 Although blinking may be used to distinguish single 
fluorophores from aggregates, it significantly complicates trajectory reconstruction in SQT  
 39 
 
Figure 2.10. Fluorescent intermittency of a single semiconductor nanocrystal. Typical 
fluorescence spectrum of a single QD is shown in A. Random alterations between dark and 
bright states constitute blinking. A fluorescence spectrum for a single, non-blinkin CdSe core 
nanocrystal coated with a 14-layer thick CdS shell is shown in B. Here, the QD spends the 
entire time interval in the bright state. 
 
and may not be a reliable indicator of single molecule fluorophores due to the dependence 
of the intermittency rate on experimental parameters and biological environment.95 To 
reduce “blinking”, a thick inorganic shell (CdS, CdZnS) with reduced lattice mismatch is 
grown around the QD core (Figure 2.10 B).146,147 Although these thick shells dramatically 
reduce fluorescent intermittency of QDs, they result in the hydrodynamic diameter increase, 
which is undesirable for biological applications.  
 
2.13. Summary 
It is clear that QDs have emerged as an attractive class of photoluminescent probes 
since their introduction to the field in 1998. Recent advances in nanocrystal surface 
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chemistry resulted in more compact and more stable QDs. Their relatively small size, 
excellent stability at physiologically relevant conditions, and unique optical properties permit 
biological investigation of cellular processes with unprecedented spatio-temporal resolution 
in real time. While QDs have already been established as powerful biological imaging agents, 
their use in the fields of diagnostics and targeted drug delivery is being actively explored. 
Utilizing their spectral characteristics, QDs can potentially form the basis of multiplexed 
fluorescence assays that examine individual protein-protein interactions and ultimately 
interrogate cell signaling pathways. Also, their robust inorganic nature renders QDs resistant 
to degradation and photobleaching for long periods of time and thereby guarantees a bright 
future for QDs as reporters of dynamic activity of biological molecules at the single-
molecule level.  
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CHAPTER III 
 
ENSEMBLE AND SINGLE QUANTUM DOT FLUORESCENCE METHODS 
IN NEUROTRANSMITTER TRANSPORTER RESEARCH 
 
3.1. Introduction 
Traditional biochemical and genetic approaches have contributed the majority of the 
existing research knowledge on NTT structure, function, and regulation. It is now apparent 
that NTT function is tightly regulated through multiple posttranslational mechanisms 
including interactions with a plethora of kinases, receptors, and scaffolding elements.1-5 
Consequent dynamic changes in NTT subcellular localization fundamentally impact the 
amplitude, duration, and specificity of NTT-mediated neurotransmitter signaling. Therefore, 
ability to “see” NTTs with subcellular resolution and to monitor dynamic trafficking 
pathways involved in NTT regulation becomes a critical tool in advancing our understanding 
of the molecular mechanisms underlying NTT signaling network.  
Recent advances in fluorescence-based techniques for molecular biology permitted 
investigation of cellular signal transduction cascades with unprecedented spatiotemporal 
resolution.6,7 Currently, there are several classes of fluorescent probes available to 
investigators. Among these, the most prevalent fluorophores are organic, dyes, genetically 
encoded fluorescent proteins, and semiconductor nanocrystals, colloquially known as 
quantum dots (QDs).8-15 General properties, advantages, and drawbacks of the 
aforementioned fluorophores are summarized in Table 3.1. Our group is primarily focused 
on exploiting the unique photophysical properties of QDs (excellent brightness, narrow  
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Table 3.1 Comparison of the photophysical properties of the commonly encountered 
fluorescent probes.  
 
emission spectra, broad excitation spectra, and superior photostability) to study subcellular 
distribution and dynamic regulation of NTTs.16-23  
There are several methodological approaches to enable specific targeting of 
membrane proteins in live cells with the aforementioned fluorescent probes (Table 3.2). 
Most commonly, (1) a fluorescent protein (e.g., EGFP) is fused to the terminus of the target 
protein and expressed in the cell of interest, or (2) a fluorophore is attached to an antibody 
targeting the extracellular domain of the target protein. Unfortunately, limited availability of 
such extracellular antibodies for NTTs and lack of suitable extracellular epitopes within the 
NTT structure have significantly hampered fluorescence-based investigation of NTT 
localization and regulation, particularly in endogenous systems. To this end, we pioneered a 
ligand-conjugated QD-based approach that utilizes a transporter-specific organic ligand 
composed of (1) a high-affinity parent drug that enables recognition of specific binding sites 
within the transporter structure and facilitates pseudo-irreversible binding, (2) a hydrophobic 
 52 
 
Table 3.2. Methodological approaches that enable specific targeting of 
neurotransmitter transporters.  
alkyl spacer which permits sufficient flexibility and provides a hydrophobic interface for a 
successful drug-binding pocket interaction, (3) a PEG polymer that aids in aqueous solubility 
and abolishes possible nonspecific interactions with the plasma membrane, and (4) a biotin 
moiety that allows subsequent streptavidin-conjugated QD recognition upon the transporter 
binding event (Figure 3.1).16-23 
In this chapter, we outline three fluorescence-based techniques that have been 
successfully applied to measure spatiotemporal changes in NTT localization and to establish 
dynamic imaging of individual NTT molecules using our ligand-conjugated QD approach.  
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Figure 3.1. Structure schematic of tailored organic ligands targeting plasma 
membrane monoamine transporters. Reprinted with permission from Ref 21. Copyright 
2011 American Chemical Society. 
First, we discuss how to label and image membrane NTTs in live cells using QD 
probes in conjunction with ensemble fluorescence microscopy. Second, we present a more 
quantitative, flow cytometry-based protocol, particularly useful for assessing transporter 
internalization and recycling. Third, as dynamic trafficking of NTTs in the plasma membrane 
appears to be an important posttranslational regulatory mechanism, we describe a single-
molecule microscopy protocol for determining the mobility of QD-bound transporters in 
the plasma membrane of live cells.  
 
3.2. Materials: HEK293 Cell Culture and Reagents 
1. DMEM medium (Gibco, Invitrogen Life Science, Bethesda, MD). 
3. Phenol Red-free DMEM medium (Gibco, Invitrogen Life Science, Bethesda, MD). 
4. Fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA). 
5. 0.05% Trypsin/EDTA (Cellgro, Mediatech). 
6. L-Glutamine (Gibco, Invitrogen Life Science, Bethesda, MD). 
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7. T25/T75 flasks; 24-well or 96-well culture plates (BD Biosciences, Falcon). 
8. Penicillin (10,000 U/mL) and streptomycin (10 mg/mL) solutions are frozen at −20°C 
(Gibco, Invitrogen Life Science); 5 mL is added to 0.5 L of DMEM complete culture 
medium. 
9. Cell line: HEK293 cells transiently or stably expressing NTT of interest.  
10. 0.1 mg/mL poly-D-lysine solution in sterile H2O.  
11. Lab-Tek chambered #1.0 borosilicate cover glass (eight-well chamber). 
12. Biotinylated ligand (1 mM stock solution in sterile H2O stored dessicated at -20°C). 
13. Bovine serum albumin (BSA). 
14. Streptavidin-conjugated quantum dots (SavQD605), with the emission maximum at 605 
nm (Invitrogen Life Science, Bethesda, MD). Optimal filter is HQ 605/20 emission for 
QD605. QDs can be excited at any wavelengths, but 488-nm is a commonly utilized 
excitation line to minimize photodamage, QD blinking, and spectral cross-talk.  
15. Cell Stripper, non-enzymatic dissociation buffer (Gibco, Invitrogen Life Science, 
Bethesda, MD). 
16. Cell culture incubator, 37°C, 5% CO2. 
17. Vacuum pump for cell washes.  
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3.3. Equipment, Software, and Accessories. 
1. LSM 510 (Carl Zeiss) or LSM 710 (Carl Zeiss) equipped with a 63x 1.4 NA Apochromat 
oil-immersion objective lens and a 488-nm excitation line (Ar laser or solid-state diode laser); 
LSM 510/710 image acquisition/analysis software or ImageJ (NIH image analysis freeware) 
to process time-lapse and z-stack fluorescence images; microscope-mounted environmental 
chamber.  
2. 3- or 5-laser Beckton-Dickinson (BD Biosciences, San Jose, CA) bench-top flow 
cytometer equipped with a multiwall plate sample cube; 12x75 mm polystyrene flow 
cytometry tubes (BD Biosciences, San Jose, CA); FlowJo flow cytometry data analysis 
package (TreeStar, Ashland, OR). 
3. High-speed, line-scanning Zeiss 5 Live confocal microscope equipped with a 63x 1.4 NA 
oil-immersion objective lens and a 488-nm 100-milliwatt solid-state diode laser; microscope-
mounted environmental chamber; Zeiss LSM Image Examiner software; MatLab or IDL-
based programming routines for analysis of real-time QD trajectory data.  
4. Imaging medium: phenol red-free DMEM supplemented with 1% BSA.  
 
3.4. Methods 
For the purpose of this chapter, it is assumed that the NTT of interest is expressed in 
HEK293 cells; however, the general principles and protocols described below remain valid 
for any expression system being used.  
3.4.1.Ensemble Microscopy Protocol 
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1. HEK293 cells are cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 
100 units/mL penicillin, and 100 mg/mL streptomycin and maintained at 37°C with 5% 
CO2. For ensemble imaging, cells are plated in poly-D-lysine-treated (1 hour at at 37°C) 
eight-well Lab-Tek chambered coverglass at a density of 1 x 105 – 1 x 106 cells and cultured 
for 24 hours prior to imaging.  
2. Prior to labeling, wash the cells gently three times with warm phenol red-free culture 
medium. 
3. Incubate cells with a biotinylated ligand (0.1-1 µM) in phenol red-free DMEM for 5-20 
min at 37°C. In the meantime, prepare a SavQD605 labeling by diluting SavQD605 stock 
solution in warm imaging buffer to reach a desired concentration of (0.5-2 nM) and incubate 
it in a 37°C water bath for 10 min.  
4. Wash the cells three times with warm phenol red-free DMEM. 
5. Incubate the cells with SavQD605 solution for 5 min at 37°C and wash at least three times 
with warm imaging buffer. 
6. Immediately post-labeling, place the chambered coverglass on the microscope with the 
mounted environmental chamber.  
7. Acquire fluorescent images at 37°C. Example data are shown in Figure 3.2.  
3.4.2. Flow Cytometry Protocol 
1. Cells are plated in a poly-D-lysine-treated (1 hour at at 37°C) 24-well/96-well culture plate 
at a density of 1-5 x 105 cells/mL 48 hours prior to the flow cytometry assay.  
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Figure 3.2. Labeling of dopamine transporter (DAT) with ligand-conjugated QDs in 
live cells. (left) streptavidin-conjugated QDs were used to label DATs previously 
exposed to a biotinylated, PEGylated cocaine analog. (A1) QD labeling of membrane 
DATs in a live HeLa cell. (B1) QD-bound DATs underwent acute redistribution from the 
plasma membrane to intracellular compartments as a result of protein kinase C (PKC) 
activation. Reprinted with permission from Ref 20. Copyright 2011 American Chemical 
Society. 
 
2. Prior to labeling QD conjugate labeling, wash the cells three times with warm DMEM and 
incubate with a drug for 10-30 min in complete culture medium at 37°C and 5% CO2. 
Parallel control wells are incubated with either drug-free complete culture medium (positive 
control) or in the presence of a high affinity transporter inhibitor (negative control). 
3. Wash the cells three times with warm phenol red-free DMEM and incubate with 
biotinylated ligand (0.1-1 µM)/drug mixture for 10 min at 37°C in warm phenol red-free 
DMEM. 
4. Wash the cells three times with ice-cold imaging buffer and incubate with previously 
prepared SavQD605 labeling solution in ice-cold imaging buffer.  
5. Wash the cells gently three times with the ice-cold imaging buffer and add Cell Stripper 
solution. Incubate for 5-10 minutes at 37°C.  
6. Analyze cell QD fluorescence using a flow cytometer. 
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7. Data are typically collected from >10,000 cells per sample, with median fluorescence 
intensity as one of the recorded fluorescent signal parameters. 
8.  By utilizing median fluorescence intensity (MFI) parameter obtained from control cell 
populations, it is possible to compute the percentage of DAT molecules unavailable for 
binding (PI, percent inhibition) according to the equation below: 
     
                  
              
        [2] 
where MFIpos is MFI of  a positive control (QD-ligand-labeled cells), MFIneg is MFI of  a 
negative control (QD only-labeled cells), and MFItreated is MFI of  a cell population incubated 
with a certain DAT modulator dose and subsequently labeled with ligand-conjugated QDs.22 
Example data are shown in Figure 3.3. 
3.4.3. Single-Molecule Microscopy Protocol 
1. Cells are plated in poly-D-lysine-treated (1 hour at at 37°C) eight-well Lab-Tek chambered 
coverglass at a density of 1-5 x 104 cells and cultured for 24 hours prior to imaging. 
2. Prior to labeling, wash the cells gently three times with warm phenol red-free culture 
medium. 
3. Incubate cells with a biotinylated ligand (1-100 nM) in phenol red-free DMEM for 5-20 
min at 37°C. In the meantime, prepare a SavQD605 labeling by diluting SavQD605 stock 
solution in warm imaging buffer to reach a desired concentration of (0.05-0.5 nM) and 
incubate it in a 37°C water bath for 10 min.  
4. Wash the cells three times with warm phenol red-free DMEM. 
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Figure 3.3. Flow cytometry-based screening of the inhibitory activity of GBR12909, a 
high-affinity DAT antagonist, using antagonist-conjugated QDs. DAT-expressing 
HEK cells were treated with five- or ten-fold dilutions of GBR12909. Percent inhibition at 
increasing doses of GBR12909 is represented as a heat map (top left) and representative 
histogram plots of the effects of increasing GBR12909 doses (top right) on QD conjugate 
binding are shown. The heat map and IC50 curve (bottom) were generated using median QD 
fluorescence intensity values. Reprinted with permission from Ref 23. Copyright 2012 Royal 
Chemical Society. 
 
5. Incubate the cells with SavQD605 solution for 5 min at 37°C and wash thoroughly at least 
three times with warm imaging buffer to remove unbound QDs. 
6. Immediately post-labeling, place the chambered coverglass on the microscope with the 
mounted environmental chamber. 
7. Acquire time-lapse fluorescent images at 37°C immediately after the final wash step. 
Typically, the final wash step is carried in the immediate vicinity of the imaging system.  
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8. Live imaging should not exceed 30 min at 37°C for cell survival and is optimally carried 
out within the initial 10-15 minutes to limit turnover of QD-bound membrane NTT 
molecules.  
9. Real-time, time-lapse image recording is obtained with an integration time of 25-100 
milliseconds for at least 500 consecutive frames. Example series are shown in Figure 3.4. 
 
Figure 3.4. Time-lapse image series depicting movement of cell surface QD-bound 
transporters. 
 
10. Real-time trajectory data is subsequently obtained from the recorded time-lapse image 
series and analyzed using custom programs written in Matlab or IDL programming software. 
Tracking analysis sequence is illustrated in Figure 3.5.  
 
3.5 Troubleshooting and Notes 
1. Optimal plating density and cell health are critical to keep weakly adherent cells, such as 
HEK293, from detaching off the Lab-Tek chambered coverglass throughout the protocol. 
Treatment of the chambered coverglass with poly-D-lysine solution is a necessary step to 
ensure the cells remain adhered to the glass bottom throught the extensive series of 
incubation and wash steps. Also, it is of utmost importance that one carefully examines cell 
morphology and overall cell health prior to acquiring fluorescence data. 
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Figure 3.5. Schematic illustrating trajectory data analysis in a typical single-QD 
tracking experiment. (a) Example of QD-DAT trajectories on the surface of transfected 
HEK293 cells. Scale: 1 pixel = 200 nm. (b) A histogram showing diffusion coefficients 
determined for the trajectories in a. (c) Averaged mean square displacement (MSD)-time plot 
of QD trajectories. Ensemble diffusion coefficient is estimated via the linear fit of 2-5 MSD-
time plot data points. 
 
2. One of the most important variables for a successful experiment is adequate quality and 
quantity of washings after drug, biotinylated ligand, and QD incubation. One must wash 
extensively after each separate step to remove excess, unbound probes, as they have the 
potential to interfere with subsequent recognition events and ultimately affect the specificity 
of QD labeling. Additionally, it is imperative that one always prepares fresh working 
solutions the day of the experiment. 
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3. The most critical determinant of experimental success is the specificity of biotinylated 
ligand binding. One must find optimal ligand concentration and incubation time to 
maximize specific binding. In our experience, 0.1-1 µM and 5-20 min ranges for ligand dose 
and incubation time respectively are typically a good starting point. In all cases, one must run 
parallel control samples to ensure labeling specificity. The control samples usually are to (1) 
apply the same labeling conditions to parental cells not expressing the transporter of interest, 
(2) include a high-affinity inhibitor to block the specific binding site during the labeling 
protocol, and (3) label transporter-expressing cells with only the QD probes to assess the 
degree of nonspecific QD binding and the effectiveness of wash steps.  
4. Another important aspect of assuring labeling specificity is the addition of a common 
blocking agent, such as BSA, to the QD solution and the imaging buffer. QD nonspecific 
binding varies significantly among cell types, and one must take great care to optimize the 
blocking conditions (Figure 2.6). Common blocking reagents are BSA, FBS, horse serum, 
gelatin, and nonfat dry milk.  
 
Figure 3.6. Comparison of nonspecific cell surface binding of 50 nM AMP™ Dots 
(A1-F1) and PEGylated AMP™ Dots (A2-F2). Nonspecific binding was found to be 
dependent upon the cell type, and conjugation of methoxy-terminated PEG2000 to the 
surface of AMP™ Dots resulted in significant reduction of nonspecific cellular binding. 
Figure reproduced with permission from Ref 40. Copyright 2005 American Chemical 
Society. 
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5. As QD-bound NTTs are subject to dynamic protein turnover, fluorescence data 
acquisition must be conducted immediately after the final wash step, especially in the case of 
single-molecule experiments. This helps prevent transporter endocytosis and allows adequate 
visualization of membrane-restricted signaling events.  
6. An important cosideration is controlling the valency of the binding. This is a particularly 
critical parameter in single-molecule experiments, as multivalent QD labeling leads to protein 
cross-linking that may inadvertently trigger downstream signal transuction cascades. To this 
end, there are two common solutions. One involves preincubation of SavQDs with the 
biotinylated ligand at ~1:1 ratio in a borate buffer (pH ~8.5) for 0.5-24 hours at room 
temperature with constant stirring; the other involves a two-step labeling protocol as 
described above and the use of ~equimolar doses of biotinylated ligand and SavQDs. In the 
case of endogenous expression systems, this requirement can be relaxed, as the low surface 
density of transporters is the primary determinant of monovalent labeling. 
7. QD density must be adjusted accordingly to ensure maximum signal-to-noise ratio in 
ensemble imaging and permit observation of 10-20 individual QDs on the cell surface in a 
single-molecule experiment. This is achieved via titrating the QD concentration while 
keeping the concentration of biotinylated ligand constant.  
8. Table 3.3 provides a set of troubleshooting instructions for a typical single-molecule 
experiment.38,39  
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Table 3.3. Troubleshooting a single-QD imaging experiment. 
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CHAPTER IV 
 
VISUALIZATION OF THE COCAINE-SENSITIVE DOPAMINE 
TRANSPORTER WITH LIGAND-CONJUGATED QUANTUM DOTS 
 
 
4.1. Introduction 
Dopamine (DA) is a modulatory neurotransmitter in the central nervous system 
(Figure 4.1).1-3 The dopaminergic system modulates a variety of physiological functions and 
behavioral responses including attention, arousal, cognition, reward, and motor activity.3 
Impaired DA signaling has been linked to a number of neurodegenerative and psychiatric 
disorders such as attention deficit/hyperactivity disorder (ADHD), bipolar disorder, major 
depression, Tourette’s syndrome, Parkinson’s disease, and schizophrenia.4-8 The synaptic DA 
concentration dictates that postsynaptic DA signal transduction and is determined by the 
activity of the presynaptic D2 dopamine autoreceptor, which modulates DA release, and the 
dopamine transporter (DAT) 1,9, which clears DA to achieve DA inactivation and recycling10. 
DAT (SLC6A3) is a member of a family of Na+-coupled solute transporters whose 
substrates include neurotransmitters, nutrients, osmolytes, and amino acids (Figure 3.1). 
Several reports have demonstrated that experimental DAT deficiency results in pronounced 
changes in dopaminergic tone and locomotor hyperactivity.10-12 In addition, DAT is the 
primary target for widely used psychostimulants, such as amphetamine and cocaine, which 
acutely modify the synaptic DA concentration. Cocaine is a competitive DAT inhibitor and 
attenuates DA clearance by occupying the DAT native substrate binding site, whereas  
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Figure 4.1. Structures of DAT and its relevant substrates. A two-dimensional topology 
of DAT based on the leucine transporter (LeuT) is shown with 12 transmembrane segments, 
intracellularly oriented N- and C-termini, and substrate binding site. Structures of dopamine, 
cocaine, and cocaine analog β-CFT are shown as well. The binding site for dopamine, 
cocaine, and cocaine analogs has been suggested to overlap and is buried deep between 
transmembrane segments 1, 3, 6, and 8. Adapted from ref. 39. 
 
amphetamine promotes DAT-mediated DA efflux that results in the increased DA synaptic 
concentration.13 DAT activity has also been demonstrated to be a subject of acute, dynamic  
regulation by several post-translational mechanisms, such as constitutive endocytosis, protein 
kinase C (PKC)-dependent internalization, protein-protein interactions, and substrate-
induced changes in surface expression level.13,14 The spatial organization and temporal 
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control of these mechanisms remains largely unknown and may be critically important in 
setting risk for disorders linked to compromised DA signaling.  
The investigation of DAT regulation has thus far trailed similar efforts directed at 
membrane receptors and channels due a number of important challenges. First, it has been 
notoriously difficult to obtain neuronal cultures due to the relatively low number of DAT-
expressing neurons.15 Therefore, much knowledge regarding DAT regulation has come from 
studies on heterologous expression systems. Second, the lack of an efficient antibody against 
an extracellular epitope does not allow direct localization and visualization of DAT 
molecules in living cells without prior chemical processing (fixation and permeabilization).16 
Third, the use of popular fusion tags, such as green fluorescent protein (GFP) and 
hemagglutinin (HA), requires genetic perturbation of DAT and thus does not allow direct 
visualization of endogenous DAT. Fourth, traditional autoradiographic, biochemical, and 
optimal techniques to monitor DAT expression, function, cellular distribution suffer from 
suboptimal spatial and temporal resolution and are limited to providing ensemble-averaged 
information.17,18 Recently, a series of dye-conjugated fluorescent cocaine analogs has been 
developed and successfully used to directly visualize DAT in living cells for the first time. 
Cha, Eriksen and colleagues used an organic dye-conjugated 2β-carbomethoxy-3β-(3,4-
dichlorophenyl)tropane (RTI 111) ligand to visualize changes in DAT cellular movement in 
response to different stimuli via laser confocal microscopy.16  
In our group, we have focused on developing new DAT-specific ligands for 
conjugation with nanometer-sized semiconductor nanocrystals, known as quantum dots 
(QD). QDs offer several distinct advantages over conventional fluorophores and permit 
visualization of membrane-associated proteins with high accuracy and temporal resolution, 
with reported values as low as 10 nm with 10 ms integration time.19-23 Specifically, their 
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excellent brightness and superior resistance to photodegradation enable noninvasive 
imaging of complex biological processes with high signal-to-noise ratio (SNR) over time 
scales from milliseconds to hours. Also, their broad absorption spectra and size-
dependent, narrow, symmetric emission spectra considerably simplify multiplexed 
molecular imaging experiments. We have previously reported the synthesis of 
GBR12909- and GBR12935-based DAT-specific ligands for conjugation with QDs.24,25 
In this effort, we sought to improve the design of the DAT ligand by incorporating a 
phenyltropane-based dopamine reuptake inhibitor parent compound (β-CFT, WIN 
35,428) into the structure.  β-CFT is a structural analog of cocaine and is 3-10x more potent 
than cocaine and is characterized by excellent structural stability.26,27 Our choice of the parent 
compound is also validated by multiple instances of the use of radiolabeled β-CFT to map 
DAT distribution in the animal and human brain.28-31  
Here, we present a relatively simple and rapid approach for QD-based direct 
visualization of DAT in living cells that uses a DAT-specific, biotinylated 2-β-
carbomethoxy-3-β-(4-fluorophenyl)tropane (IDT444) in conjunction with SavQDs. We 
demonstrate the specificity of DAT QD labeling and the ability to detect DAT-expressing 
mammalian cells at a combination of low nanomolar concentrations of IDT444 and 
picomolar concentrations of QDs. To determine whether we could use our QD-based 
approach to capture DAT trafficking, we visualized acute, protein kinase C (PKC)-
dependent internalization of DAT-QD complexes in response to phorbol ester treatment. 
Finally, we show the advantages of QD photophysical properties in time-lapse image series 
acquisition over extended periods of time. 
 
4.2. Results and Discussion 
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4.2.1. Cocaine analog synthesis 
To develop a DAT-specific probe, a biotinylated cocaine analog IDT444 (6) was 
synthesized (Figure 4.2 A). The IDT444 ligand is composed of four distinct parts: (i) a high-
affinity cocaine analog, 2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane (β-CFT or WIN 
35,428), first reported by Clark et al., (ii) a short alkyl spacer, (iii) a PEG chain (average MW 
5000), (iv) and a biotin terminus (Figure 4.2 B).26 β-CFT was chosen as the parent drug due 
to its high affinity for DAT, excellent structural stability, and pharmacological properties 
closely resembling those of cocaine.26,27 The hydrophobic alkyl linker was incorporated into 
the IDT444 ligand by attaching it to the nitrogen atom on the tropane ring. The tropane 
nitrogen was chosen as the attachment point based on previous studies, which showed that 
bulky groups attached to the tropane N-position had no significant effect on the phenyl 
tropane pharmacological properties and structural stability.27-32 The short alkyl spacer was 
attached to the tropane nitrogen to increase flexibility and allow enhanced access to the 
binding site. The PEG chain was used to ensure the IDT444 ligand is soluble in aqueous 
buffers and possibly reduce any potential nonspecific interactions with the cellular 
membrane.33 The biotin handle at the end of the PEG chain served as a binding site for 
SavQDs. Detailed synthetic steps are described in Supplementary Information available free 
of charge at http://pubs.acs.org/doi/abs/10.1021/cn200032r. 
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Figure 4.2. (A) The synthetic route used to prepare IDT4446. (B). Schematic representation 
of the two-step DAT labeling approach using IDT ligand and SavQDs. 
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4.2.2. DAT Visualization in Flp-In-293 Cells in Suspension 
The HEK Flp-In-293 cell line was used as a model stable expression system to investigate 
the interactions of our QD-based fluorescent probes with DAT. The Flp-In-293 cells 
contain a Flp Recombination Target (FRT) site introduced into their genome (Invitrogen) 
that permits insertion of different DNAs into a common genomic locus in different cell 
lines. To achieve DAT expression, a plasmid vector containing the FRT site linked to the 
hygromycin resistance gene and the DAT cDNA was integrated into the genome via Flp 
recombinase-mediated DNA recombination at the FRT site. DAT-expressing Flp-In-293 
cells were selected in the presence of 100 μg/mL hygromycin B.  
DAT-Flp-In-293 cells were subjected to a two-step solution-based QD labeling 
protocol. Flp-In-293 cells were incubated with the IDT444 ligand and subsequently labeled 
with SavQDs in solution to prevent the loss of cells due to detachment from the plate 
surface, reduce nonspecific QD interactions with the culture vessel, and enhance specific 
recognition of the biotinylated ligand. These cells were incubated with 100 nM IDT444 in 
PBS solution for 5 min at 37°C, lifted off the culture plate by gentle pipetting, centrifuged, 
and resuspended in 1 nM SavQD PBS solution for 5 min at 4°C. After several wash steps to 
rinse away the unbound ligands and conjugates, specific DAT QD labeling was 
demonstrated by confocal microscopy and flow cytometry, which were used as 
complementary techniques to quantify DAT QD labeling. Representative flow cytometry 
histograms and confocal images of the specific labeling of DAT expressed in hDAT-Flp-In-
293 cells are shown in Figure 4.3. DAT-Flp-In-293 cells pretreated with 1 µM GBR12909, a 
high-affinity DAT antagonist, and DAT-Flp-In-293 cells incubated with 1 nM SavQDs only 
were used as control cell populations.34,35 Compared to the control samples, the prominent 
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increase of the median fluorescence intensity (MFI) as assessed by flow cytometry (Figure 
4.3, A3) and the presence of membrane-associated uniform fluorescent halos on the 
 
Figure 4.3. Specific SavQD-IDT444 labeling of DAT stably expressed in Flp-In-293 
cells. Representative flow cytometry histograms and confocal images are shown for DAT-
expressing cells (A1-A3), DAT-expressing cells pretreated with 1 μM GBR12909 (B1-B3), 
and DAT-expressing cells incubated with SavQD only (C1-C3). All samples were incubated 
with 100 nM solution of IDT444 in PBS for 5 min at 37°C and subsequently exposed to 1 
nM SavQD in PBS for 5 min at 4°C. 
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acquired confocal images (Figure 4.3, A1-A2) indicated successful, specific hDAT QD 
labeling. GBR12909 effectively blocked the interaction of SavQD-IDT444 conjugates with 
hDAT (Figure 4.3, B1-B3), and the cell population exposed to SavQDs only (Figure 4.3, C1-
C3) had similarly low percentage of labeled cells as observed for the preblocked cell 
population, indicating minimal ligand nonspecific binding. The images and flow cytometry 
histograms shown in Figure 4.3 are representative of at least 5 independent experiments. 
 
4.2.3. IDT444 and SavQD Dose Response 
Next, we investigated the sensitivity of flow cytometric detection of DAT-Flp-In-293 
cells using our QD-based approach. In the first series of dose-response experiments, the 
SavQD concentration was kept constant at 1 nM, and IDT444 concentration was varied 
over several orders of magnitude (10 pM – 1 μM). The cell populations were subjected to 
the two-step labeling protocol described above and analyzed by flow cytometry. Parallel 
DAT-Flp-In-293 cells preblocked with 1 μM GBR12909 were used as a control to assess 
ligand nonspecific binding at different IDT444 concentrations. The IDT444 concentration-
response curves are shown for both cell populations in Figure 4.4 A. Each data point 
represents the averaged MFI from three independent experiments. Robust standard 
deviation (rSD) was calculated from the MFI and the robust coefficient of variation (rCV) of 
the fluorescence intensity distribution (See SI). We observed statistically significant 
difference in MFI of labeled and control DAT-Flp-In-293 at the IDT444 concentration of 1 
nM (p < 0.05). Also, it is apparent from the control population MFI curve that the increase 
of IDT444 concentration over several orders of magnitude does not result in significant 
ligand-mediated nonspecific binding. This suggests that DAT detection in Flp-In-293 cells is  
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Figure 4.4. IDT444 (A) and SavQD (B) dose response curves. Individual data points represent 
averaged MFI from three independent experiments. Robust standard deviation (rSD) was calculated 
from the MFI and the robust coefficient of variation (rCV) of the fluorescence intensity distribution 
(See SI). 
 
ligand-specific and dose-dependent. In the second series of dose-response experiments, 
IDT444 concentration was kept constant at 100 nM, and SavQD concentration was varied 
over several orders of magnitude (10 pM - 10 nM). Parallel DAT-Flp-In-293 cells preblocked 
with 1 μM GBR12909 were used as a control to assess QD nonspecific binding at different 
concentrations. We observed statistically significant difference in MFI of labeled and control 
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DAT-Flp-In-293 at SavQD concentration as low as 100 pM (p < 0.05, Figure 4.4 B). It 
should be noted that the MFI of the control population increased significantly with the 
increasing SavQD dose. This indicates that one must carefully optimize the concentration of 
QDs to be used in our approach, since the SNR will be dependent on the QD surface 
chemistry as wells as cell type.33 Here, we determined that we could successfully detect Flp-
In-293 cells stably expressing DAT at a combination of low nanomolar concentrations of 
IDT444 and picomolar concentrations of SavQDs.  
 
4.2.4. DAT Visualization in HeLa Cells in situ 
After we successfully demonstrated specific QD labeling of DAT in stably 
transfected Flp-In-293 cells in suspension, we attempted to visualize Flp-In-293 cells in 8-
well chamber slides in situ. This proved to be a very challenging task since Flp-In-293 cells 
are weakly adherent and detach easily during gentle washes between labeling steps even in 
collagen- and fibronectin-coated chamber slides. Therefore we chose a relatively strongly 
adherent HeLa cell line to determine whether we could use our approach to label living 
DAT-expressing cells in situ. HeLa cells were transiently transfected with a pcDNA3 vector 
containing the human DAT cDNA in 8-well chamber slides. Parallel HeLa cells were 
transfected with an empty (sham) pcDNA3 vector and served as a negative control to 
evaluate nonspecific cell labeling. Just prior to confocal imaging, DAT-transfected HeLa 
cells were incubated with 100 nM IDT444, washed 3x with warm imaging buffer, incubated 
with 1 nM SavQD, washed 3x with warm imaging buffer, and QD-labeled HeLa cells were 
subsequently visualized (Figure 4.5, A1-A2). Confocal images clearly demonsrate uniform 
plasma membrane labeling of DAT-transfected cells. No fluorescence staining was observed 
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for DAT-transfected HeLa cells preincubated with 1 μM GBR12909 (Figure 4.5, B1-B2) and 
sham-transfected HeLa cells (Figure 4.5, C1-C2), indicating a low level of nonspecific 
labeling. These data demonstrate that our QD-based approach can be used to specifically 
label DAT in living cells in situ with high SNR. 
Figure 4.5. Specific SavQD-IDT444 labeling of DAT stably expressed in living HeLa 
cells in situ. Representative confocal images are shown for DAT-pcDNA3 transiently 
transfected HeLa cells (A1-A2), DAT-pcDNA3 transiently transfected cells pretreated with 1 
μM GBR12909 (B1-B2), and Sham-pcDNA3 transiently transfected cells (C1-C2). 
Fluorescent (Top) and overlay (Bottom) images are shown. All samples were incubated with 
100 nM solution of IDT444 in the imaging buffer for 5 min at 37°C and subsequently 
exposed to 1 nM SavQD in the imaging buffer for 2-3 min at 37°C. Images are 
representative of at least 5 independent experiments. 
 
4.2.5. Visualization of PKC-Dependent DAT Internalization 
It has been demonstrated that PKC activation by phorbol esters, such as phorbol 12-
myristate 13-acetate (PMA), results in acute down-regulation of DAT surface expression  
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levels in several heterologous cell lines.36-38 To investigate whether we could use our IDT444-
SavQD conjugates to visualize acute DAT internalization, we incubated transiently 
transfected HeLa cells with 100 nM IDT444 for 5 min at 37°C, washed the cells 3x with 
warm imaging medium, incubated the cells with 1 nM SavQD for 2-3 min 37°C, and washed 
the cels 3x with warm imaging medium. QD-labeled HeLa cells were then incubated for 30 
min at 37°C in the presence or absence of 1 μM PMA. While we did not observe any 
apparent change in the distribution of membrane DAT-QD complexes in HeLa cells 
incubated in the presence of vehicle (DMSO) only (Figure 4.6, A,C), PMA treatment led to  
 
Figure 4.6. Visualization of DAT internalization in HeLa cells transiently expressing DAT using 
IDT444-SavQD conjugates. PMA promotes internalization of the DAT-QD complex in live HeLa 
cells transiently transfected with DAT-pcDNA3. The cells were incubated with 100 nM solution of 
IDT444 in the imaging buffer for 5 min at 37°C and subsequently exposed to 1 nM SavQD in the 
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imaging buffer for 2-3 min at 37°C before incubation in the absence (A1-A2) or presence of 1 μM 
PMA (B1-B2) for 30 min at 37°C. Images are representative of at least 3 independent experiments. 
 
the appearance of punctate intracellular fluorescence, a clear sign of acute, PKC-dependent 
DAT-QD complex internalization consistent with the previous reports (Figure 4.6, B,D). 
This experiment demonstrates the applicability and utility of our QD-based labeling 
approach in the investigation of DAT regulation in living cells.  
 
4.2.6. Quantum Dot Photostability  
To demonstrate that our QD-based labeling approach can be used as a tool to visualize 
DAT over extended periods of time, we compared SavQDs to a standard organic dye FITC. 
Individual 8-bit images (512 x 512 pixels, 1 Airy unit) were acquired every 30 seconds for 10 
min at a scan speed of 51.20 μsec/pixel, with laser intensity set to 20% (Figure 4.7, A-C). 
Fluorescence intensity of QD or FITC DAT membrane labeling in Flp-In-293 cells was 
quantified, normalized, and plotted as a function of acquisition time (Figure 4.7 D). Each 
data point represents average integrated membrane fluorescence intensity for 6 cells from 
two independent experiments. In the case of FITC, bleaching occurs within 300 s (Inorm < 
0.2), whereas the intensity of QD labeling undergoes minimal decrease within 600 s. The 
photobleaching issue becomes important when one is monitoring biological processes for 
longer periods of time at high temporal resolution. Excellent photostability of QDs makes 
our QD-based labeling approach an excellent candidate for monitoring changes in DAT 
surface expression level and cellular localization for prolonged periods of time at temporal 
resolution higher than that allowed by the use of traditional fluorophores.  
 82 
 
 
Figure 4.7. Photostability comparison between QD655 and FITC. (A) Top row: DAT-Flp-In-293 
cells labeled with IDT444 and SavFITC. Bottom row: DAT-Flp-In-293 cells labeled with IDT444 and 
SavQD655. The time-lapse image series were acquired on the Zeiss LSM 510 inverted confocal 
microscope with the 488-nm excitation laser, a 650-nm long pass filter (QD) or a 505-550-nm band 
pass filter (FITC), and Zeiss Plan-Apo oil immersion objective (63X, NA 1.40). Images (512x512 
pixels, 1 Airy unit) were acquired every 30 seconds for 10 min at a scan speed of 51.20 μsec/pixel, 
with laser intensity set to 20%. Images at 0, 120, and 240 s are shown. (B) Quantitative analysis of 
changes in intensities of SavQD655 and SavFITC. Membrane-associated intensity was quantified for 
each frame by integrating fluorescence intensity over a manually drawn region encompassing the 
membrane area, with DIC images serving as a reference point (Metamorph). Intensity values were 
normalized with respect to the highest intensity value obtained (I/I0, where I0 = Imax). 
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4.3. Conclusion 
To summarize, our goal for the current effort was to develop a DAT-specific ligand 
and demonstrate specific labeling of cell surface DAT using QD-based detection. The 
biotinylated derivative of the β-CFT cocaine analog, IDT444, was prepared by attaching the 
biotin-PEG-alkyl group to the tropane nitrogen. The ability to visualize mammalian cells 
stably expressing DAT with SavQD-IDT444 conjugates was clearly demonstrated by flow 
cytometry and confocal microscopy for Flp-In-293 cells in suspension and HeLa cells in situ. 
We determined that DAT-expressing cells could be detected at a combination of low 
nanomolar concentrations of IDT444 and picomolar concentrations of SavQDs, as assessed 
by flow cytometry. The relatively high sensitivity of our approach in combination with short 
sample preparation time renders IDT444 useful in a quantum dot-based fluorescent assay to 
monitor DAT expression, function, cellular distribution, and regulation. Specifically, we 
demonstrated the applicability and utility of our approach in the visualization of acute, PKC-
dependent DAT internalization. Due to its sensitivity and flexibility, the quantum dot-based 
fluorescent assay platform we describe can potentially replace conventional biochemical and 
radiolabeled isotope-based approaches to study the distribution and regulation of DAT 
proteins. If issues related to blood-brain barrier penetration of QDs can be overcome, it is 
not unreasonable to consider whether our approach might not also be of diagnostic utility 
for perturbations of in vivo DAT levels in addiction, neuropsychiatric or neurodegenerative 
disorders. Finally, our QD-based approch should allow appropriation of the unique 
photophysical properties of QDs to achieve time-lapse imaging of DAT molecules in living 
cells for prolonged periods of time combined with improved temporal resolution, providing 
new opportunities to elucidate the molecular mechanisms supporting DAT regulation. 
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CHAPTER V 
 
A FLOW CYTOMETRY-BASED DOPAMINE TRANSPORTER BINDING  
ASSAY USING ANTAGONIST-CONJUAGTED QUANTUM DOTS  
 
5.1. Introduction 
Bioanalytical and pharmacological approaches aimed at either interrogation of  cell 
surface protein activity, distribution, and regulation, or screening for small-molecule 
modulators of  the protein function have benefited greatly from the integration of  
fluorescence-based methods.1-3 Fluorescence-based approaches greatly complement 
information attained via gold standard radioisotope-based assays, in part due to 
breakthrough advances in sensitivity and versatility of  available instrumentation and 
elimination of  concerns arising from handling and disposal of  radioactive materials. 
Moreover, it has now become possible to perform real-time kinetic measurements using 
viable cells in a multi-well plate format.4-6 
Flow cytometry has emerged as one of  the dominant fluorescence-based techniques, 
as it enables a quantitative, high-content measurement of  ligand-protein and protein-protein 
interactions in single cells; in fact, high-content flow cytometry is now an integral part of  the 
Molecular Libraries Initiative (MLI) of  the National Institutes of  Health (NIH) Roadmap.1,7-
12 In addition, flow cytometry offers truly unique multiplexing capabilities that allow 
simultaneous monitoring of  up to seventeen fluorescent parameters in addition to 
discriminating mixtures of  cells based on two physical parameters.10,12 As a result, flow 
cytometry may be used to determine both pathway and cell-type selectivity of  drug 
candidates in a routine screen.  
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There are several classes of  fluorophores available for fluorescence-based 
measurements, including genetically encoded fluorescent proteins, traditional organic 
fluorophores, and inorganic nanomaterials.13 Quantum dots (QDs), nanometer-sized 
semiconductor nanocrystals, are a particularly attractive class of  fluorescent reporters due to 
superior photostability, excellent brightness, broad absorption spectra, and narrow emission 
spectra.14-17 The latter two are particularly useful since instrumental requirements for 
multiplexing are considerably simplified as a result.  
Since 2000, the Rosenthal group has been successfully preparing novel antagonist-
conjugated QD probes that allow interrogation of  neurotransmitter transporter protein 
function, with one  ultimate goal being the development of  fluorescence-based assays to aid 
in the discovery of  more effective antidepressants and antipsychotic drugs.18-25 Recently, we 
reported the synthesis of  a dopamine transporter (DAT)-specific probe that was used in 
conjunction with streptavidin-conjugated QDs (SavQDs) to visualize membrane DATs in 
live cells.25 Our labeling approach utilized a biotinylated, pegylated, high-affinity DAT 
antagonist β-CFT (2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane (IDT444). Previously, 
radioactive forms of  β-CFT have been used in discovery of  novel DAT antagonists and 
mapping of  the distribution of  DAT in the mammalian brain.26-30 DAT is of  particular 
interest to us as it is a major target for the psychostimulants cocaine and amphetamine. 
Moreover, alterations in human DAT structure and/or function have been associated with 
schizophrenia, bipolar disorder, Parkinson’s disease, and attention deficit hyperactivety 
disorder (ADHD). As a consequence, novel DAT activity modulators represent a promising 
category of  therapeutics.35-39 
Here, we describe a flow cytometry-based assay that utilizes DAT antagonist-
conjugated QDs to assay DAT activity and regulation in live cells in a multi-well plate 
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format. The quality and performance of  the assay were initially evaluated using negative and 
positive control data. To test the versatility of  the QD-based assay, two sets of  experiments 
using known DAT modulators were performed. The QD-based platform described here 
offers a useful alternative to conventional techniques utilized to study protein function, as it 
is readily adaptable to a system of  interest and may be amenable to high-throughput 
screening (HTS) of  novel small-molecule DAT modulators.  
 
5.2. Results and Discussion 
 
Temporal stability of  a binding interaction between a fluorescent probe and its target 
protein is an important parameter in the development of  a fluorescence-based affinity 
screening assay. Thus, we first sought to determine the reversibility of  DAT QD labeling. 
DAT-expressing Flp-In-HEK-293 cells were sequentially labeled with IDT444 and SavQDs, 
washed several times with warm imaging buffer, and subsequently incubated for at least 30 
min at 37°C/5% CO2 in presence of  varying doses of  the high-affinity DAT antagonist 
GBR12909.29,30 The degree of  QD conjugate dissociation was assessed with confocal 
microscopy (data not shown here). Dissociation was not apparent even in presence of  a 
large excess of  GBR12909 (50 µM). Parallel flow cytometry analysis confirmed that QD-
IDT444 off-rate is very slow, with no statistically significant QD fluorescence loss observed 
after 30 min of  incubation. It was therefore established that the fluorescence readout could 
be reliably used to determine the amount of  surface DATs available for binding, as an 
altenative to radioligand- or antibody-based conventional techniques.  
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Next, we sought to establish a flow cytometry-based protocol that would allow 
multi-well plate screening of  both adherent and suspension cell cultures using our ligand-
conjugated QDs. The platform is depicted in Figure 5.1. Adherent DAT-expressing cells are  
 
Figure 5.1. Schematic of  a QD-based assay that uses antagonist-conjugated QDs to  
determine  inhibitory  activity  of   DAT  modulators.  IDT444 structure  and  DAT  
labeling  schematic  are  shown  in  (A).  Expected effects  of   competition  and  surface  
downregulation  of   DAT  on  QDIDT444 binding and the single-cell fluorescence intensity 
measured are demonstrated in (B). 
(i) exposed to an antagonist candidate, (ii) incubated with 100 nM IDT444/inhibitor mixture 
for 10 min, (iii) washed several times with KRH buffer and incubated with 1 nM QD/1% 
BSA (bovine serum albumin) mixture, (iv) nonenzymatically  dissociated, and (v) assayed by 
flow cytometry. With the use of  a multichannel pipette, a 24-, 48-, or 96-well plate could be 
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ready for flow cytometry analysis within an hour.  To test the robustness of  this platform, a 
Z’ statistical factor was determined using only the control data as follows: 
       
             
|       |
      [3] 
The Z’-factor takes into account the signal-to-noise ratio and s.d. of  control samples and is 
commonly utilized for quality assessment in assay development. Values of  Z’ ≥ 0.5 are 
considered excellent.31 The Z’-factor of  our QD-based assay was determined to be 0.73, 
indicating robust assay performance.  
 
Figure 5.2. Flow cytometry-based screening of  the inhibitory activity of  GBR12909, a 
high-affinity DAT antagonist, using antagonist-conjugated QDs. DAT-expressing 
HEK cells were treated with five- or ten-fold dilutions of  GBR12909. Percent inhibition at 
increasing doses of  GBR12909 is represented as a heat map (top left) and representative 
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histogram plots of  the effects of  increasing GBR12909 doses (top right) on QD conjugate 
binding are shown. The heat map and IC50 curve (bottom) were generated using median QD 
fluorescence intensity values.  
 
Once the assay quality was determined, two sets of  experiments using known DAT 
modulators were performed to evaluate its versatility. In the first set of  experiments, 
adherent DAT-expressing HEK cells were exposed to varying GBR12909 antagonist doses. 
The median fluorescence intensity (MFI) was used to estimate percent inhibition (PI) of  QD 
conjugate binding according to the equation below: 
     
                  
              
         [4] 
where MFIpos is MFI of  a positive control (QD-IDT444-labeled cells), MFIneg is MFI of  a 
negative control (QD-labeled cells), and MFItreated is MFI of  a cell population incubated with 
a certain DAT modulator dose and subsequently labeled with IDT444 and SavQDs. 
Obtained PI data were pooled from three independent experiments with triplicate samples 
to generate a dose-response curve (Figure 5.2). The half-maximal inhibitory concentration 
(IC50) of  GBR12909 was determined to be 27 ± 7 nM, which is in excellent agreement with 
values obtained using conventional techniques. Typical IC50 values reported for inhibition of  
[3H]DA transport are in the 1-50 nM range for  GBR12909.32,33 In the second set of  
experiments, DAT-expressing cells were exposed to varying concentrations of  phorbol-12-
myristate-13-acetate (PMA), a potent protein kinase C activator that leads to acute surface 
DAT downregulation.25 A dose-response curve generated from three independent 
experiments with triplicate samples is shown in Figure 5.3. As expected, surface DAT 
downregulation reached saturation at µM PMA doses, and a total of  ~50% surface DAT was 
lost after a 20-minute incubation period. The IC50 value was determined to be 20 ± 11 nM 
and was found to be in excellent agreement with the previously reported data.34 Together, 
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these experiments demonstrated that our QD-based platform could be used to accurately 
predict inhibitory activity of  both direct and indirect DAT modulators. 
 
Figure 5.3. Flow cytometry-based screening of  the inhibitory activity of  PMA using 
antagonist-conjugated QDs. DAT-expressing HEK cells were treated with five- or ten-
fold dilutions of  PMA. Percent surface DAT downregulation at increasing doses of  PMA is 
represented as a heat map (top left) and representative histogram plots of  the effects of  
increasing PMA doses (top right) on QD conjugate binding are shown. The heat map and 
IC50 curve (bottom) were generated using median QD fluorescence intensity values.  
 
5.3. Summary 
Development of  fluorescence-based binding assays that target cell surface proteins 
with unresolved crystal structures and ineffective antibodies against the extracellular epitope 
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is particularly challenging. Here, we presented a platform that addresses these issues and 
does not require genetic perturbation, chemical processing (fixation/permeabilization), or 
special handling as in the case of  radioactive materials. The QD-based flow cytometric assay 
was used to accurately measure inhibitory action of  known DAT modulators. The Z’-factor, 
a statistical measure of  assay quality and performance, was calculated to be 0.73, with the 
“excellent” rating for Z’-factor values above 0.5. The modular design of  our antagonist-
conjugated QD probes makes the platform described here readily adaptable to any cell 
surface protein system of  interest. Furthermore, our QD-based assay may also be of  
potential value to HTS of  small-molecule modulators of  DAT function, as it can be easily 
miniaturized to 384-well plates. In addition, broad absorption and narrow emission spectra 
of  QDs will allow monitoring of  several targets or cellular responses and may therefore 
establish pathway and cell-type selectivity of  DAT modulators in a high-content screen. 
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CHAPTER VI 
 
SINGLE QUANTUM DOT TRACKING OF DOPAMINE TRANSPORTER 
PLASMA MEMBRANE DYNAMICS: A LINK BETWEEM TRAFFICKING AND 
ATTENTION DEFICIT/HYPERACTIVITY DISORDER 
 
6.1. Introduction 
The high-affinity dopamine (DA) transporter protein (DAT) plays a critical role in 
maintaining coordinated, dopamine-mediated signaling in the central nervous system 
(CNS).1-6 DAT controls the intensity and duration of dopamine signals by reducing the 
extracellular concentrations of the neurotransmitter through re-uptake into presynaptic 
nerve terminals (Figure 6.1 A). Dysfunction and/or polymorphisms in DAT have been 
linked to a variety of brain disorders, including schizophrenia, bipolar disorder, dystonia, 
Parkinson’s disease, and attention-deficit/hyperactivity disorder.3-10 In addition, DAT is a 
major target for the widely abused psychostimulants, amphetamine and cocaine (Figure 6. 
1A).6 DAT has been shown to be tightly regulated through multiple mechanisms including 
phosphorylation, protein-protein interactions and membrane trafficking, mechanisms that 
can be influenced by psychoactive drugs.11-23 Over the past decade, several reports have 
demonstrated that populations of cell surface DAT molecules are associated with distinct, 
cholesterol-enriched membrane microdomains, termed “lipid rafts” and can also display 
cholesterol-dependent lateral diffusion and/or functional states. 18,20,24-27 DAT surface 
dynamics appear to depend both on localization with membrane microdomains and 
interactions with intracellular protein networks which appear to be critical for proper 
spatiotemporal regulation of DAT function.11,13-15 Despite the clear clinical importance of  
 98 
 
Figure 6.1. Dopaminergic synapse and dopamine transporter two-dimensional 
topology. (A) A diagram depicting signal transduction in the dopaminergic synapse. 
Dopamine is transported within synaptic vesicles and is released by a presynaptic neuron 
into the synaptic cleft, where it can bind to dopamine receptors on postsynaptic terminals. 
Normally, dopamine is recycled back into the presynaptic terminal by the dopamine 
transporter. Cocaine acts as a dopamine transporter antagonist, blocking dopamine reuptake 
and thereby increasing dopamine synaptic concentration. Amphetamine, on the other hand, 
depletes synaptic vesicles of dopamine and induces dopamine reverse transport through the 
dopamine transporter. Amphetamine also binds reversibly to dopamine transporter, slowing 
dopamine reuptake. (B) A two-dimensional topology of DAT based on the leucine 
transporter (LeuT) is shown with 12 transmembrane segments, intracellularly oriented N- 
and C-termini, and substrate binding site. The location of the R615C substitution in a highly 
conserved region of the transporter’s C-terminus is shown. (Adapted from Ref. 38 Copyright 
2011 American Chemical Society) 
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understanding DAT modulation, a dearth of information exists to indicate whether or how 
such regulatory mechanisms may be impacted in brain disorders. To a significant degree, 
inspection of these mechanisms has been limited by a reliance on the ensemble-averaging 
approaches available with conventional biochemical and optical techniques. 
Biomolecule detection using quantum dots (QDs), nanometer-sized semiconductor 
crystals, addresses the limitations associated with population-based optical and biochemical 
techniques, as QDs offer several key advantages over traditional fluorophores: (i) broad 
absorption spectra and narrow, Gaussian-like emission spectra (25-40 nm at full-width half-
maximum of the emission peak), (ii) high quantum yields and large molar extinction 
coefficients, (iii) superior resistance to photobleaching, and (iv) versatility of surface 
functionalization.28-30 Moreover, the use of QDs considerably simplifies the technical 
requirements for a highly sensitive, single molecule tracking experiments where observation 
of single QD-labeled targets can be achieved with ~5-10 nm accuracy over time periods that 
range from milliseconds to minutes.31,32 The primary focus of our group has been the 
development of ligand-conjugated QD probes that enable a specific targeting of neuronal 
membrane proteins, such as the serotonin (5-HT) transporter (SERT), DAT  and the 
norepinephrine (NE) transporter (NET), as well as the γ-aminobutyric acid (GABA) 
receptor.33-41 Since many membrane proteins lack surface-epitope antibodies suitable for 
dynamic tracking of single molecules, the cornerstone of our probe development has been 
the QD coupling of high-affinity, small-molecule antagonists that can provide for pseudo-
irreversible probe binding and the analysis of surface trafficking properties.39-41 Our approach 
enables both highly sensitive population detection of transporters and receptors as well as 
single QD analysis of target protein diffusion dynamics. In the most recent effort, Chang et 
al. used antagonist-conjugated QD probes in conjunction with high-speed, line-scanning 
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laser confocal microscopy to reveal a connection between receptor-mediated signaling-
pathways that alter SERT activity and the membrane dynamics of SERT proteins on the 
surface of serotonergic cells.41 
Here we adapted our recently reported, DAT-specific probe IDT444 to establish 
dynamic imaging of single DAT-QD complexes on the surface of living cells.38,40 The 
biotinylated, PEGylated cocaine analog IDT444 provides for labeling of surface DAT 
molecules via  streptavidin-conjugated QD (SavQD) coupling to DAT-bound ligand, and 
has been shown to bind to DAT with high affinity and excellent specificity.38 In this study, 
we extend our efforts to visualize single QD-labeled DAT complexes in living cells, 
providing for a characterization of their membrane dynamics and their sensitivity to 
membrane cholesterol extraction, drug impact, and ADHD-derived coding variation. Our 
studies support a significant confinement of membrane DAT molecules to GM-1 
ganglioside enriched membrane microdomains that can be perturbed by disease-associated 
DAT coding variation. 
 
6.2. Results and Discussion 
6.2.1. Tracking Single DAT-QD Complexes 
To overcome the limitations of ensemble-averaging and poor spatiotemporal 
resolution of the currently existing arsenal of DAT probes, we developed a high-affinity, 
biotin-labeled and DAT-specific cocaine analog IDT444 that permits pseudo-irreversible 
binding to SavQDs, while retaining high-affinity interactions with DAT.38,40 The flexible 
PEG-based linker of IDT444 also reduces potential steric hindrance of QDs with the cell 
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surface in addition to enhancing water solubility of the ligand.51 With this probe strategy, we 
demonstrated previously that QD-IDT444 conjugates successfully detected plasma 
membrane-localized DATs in both transiently and stably-transfected expression systems. 
Importantly, DAT-bound QD-IDT444 conjugates displayed a very slow off-rate (>1 hr), 
allowing for prolonged visualization of surface DAT molecules.40 In the current study, we 
implemented our two-step QD labeling strategy to establish, for the first time, the dynamic 
imaging of membrane DATs in live cells with single QDs. The two-step labeling approach 
employed to detect membrane DATs is illustrated in Figure 6.2A. A representative confocal 
fluorescence image in Figure 6.2B depicts individual DAT-QD complexes on the cell 
surface. Nonspecific QD binding could be virtually eliminated by the inclusion of at least 1% 
w/w bovine serum albumin (BSA) in the QD imaging buffer. We monitored the movement 
of QD-labeled DATs in Flp-In 293 cell membranes using time-lapse image acquisition at a 
scan speed of 10 Hz over 1 min.41 It should be noted that only cell surface-bound QDs in a 
focal plane at the membrane-glass interface were detected. To minimize the effects of 
endocytosis, QD labeling was carried as the last experimental step, and QD-labeled cells 
were imaged immediately post-labeling. Also, data acquisition was achieved within 10 
minutes of the final wash step. Fluorescence intermittency, an intrinsic property of single 
nanocrystals, was used as a criterion to assure analysis of single QD events (Figure 6.2C).42-45 
An example of a DAT-QD trajectory is shown in blue in Figure 6.2D, with blinking/off 
intervals shown in red. To successfully interpolate the position of QDs between frames 
during which they blinked, IDL-based single tracking algorithms were employed (See 
Methods).  
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Figure 6.2. Time-lapse imaging of DAT in the plasma membrane of stably-
transfected Flp-In 293 cells. (A) Schematic of the QD labeling protocol. DAT-specific 
IDT444 cocaine analog accesses the high-affinity binding site of DAT. Its biotin terminus 
facilitates subsequent DAT recognition with SavQDs. (B) Fluorescence micrograph showing 
characteristic surface QD labeling of DATs. Intracellular green fluorescence is characteristic 
of DAT-mediated IDT307 transport and was used as a cell position and focal plane gauge. 
Bar: 5 µm. (C) A representative time-lapse image series of a single SavQD immobilized 
(spun-cast) on a glass coverslip and a corresponding emission spectrum trace. Emission 
spectra of single nanocrystals exhibit fluorescence intermittency, a criterion used to 
distinguish single QDs from aggregation artifacts. (D) An example trajectory of single DAT-
QD complex undergoing diffusion in the plasma membrane. 
 
6.2.2. DAT-QD Membrane Dynamics Reveals Confined Behavior 
Initially, we examined the differences in cell surface diffusive motion of individual, 
nonspecifically adsorbed  carboxyl-terminated AMP™ QDs (Figure 6.3 A, Left) in parallel 
with DAT-bound QDs in stably-transfected Flp-In 293 cells (Figure 6.3 A, Middle-Right). 
Although limited in abundance, AMP™ QDs nonspecifically bound to the cell membrane  
 103 
 
 
Figure 6.3. Single-quantum dot tracking of AMP™ QDs nonspecifically bound to 
the membrane of Flp-In 293 cells and SavQDs specifically bound to membrane 
DATs expressed in Flp-In 293 cells. (A) Single particle real-time trajectories of DAT-
bound or nonspecifically bound QDs are shown as inset zoom-ins, and instantaneous 
velocity distributions are displayed for the corresponding trajectories. (B) Trajectories 
from (A) are depicted as a displacement from the initial position (x0, y0) over time; 
trajectories appear continuous, increasing linearly with time. (C) Averaged MSD as a 
function of time for a single AMP™ QD and single DAT-QD complexes. MSD (t) plot 
for a single AMP™ QD reflects linear increase over time, indicative of simple, 
Brownian-like diffusion, whereas MSD (t) plots for single DAT-QDs are characterized 
by pronounced negative curvature at increasing lag time, indicative of confined diffusion. 
 
can be used as a background control in particle tracking studies.46,47 As expected, membrane 
dynamics of single AMP™ QDs was characterized by a continuous, Brownian-like lateral 
diffusion with no apparent transient confinement. Analysis of the instantaneous velocity of a 
single AMP™ QD revealed a broad, multimodal distribution of step sizes, with a mean 
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instantaneous velocity of 1.8 ± 0.2 µm/s. In contrast, real-time trajectory data of single 
DAT-QD complexes was characterized by much more limited lateral movement. Thus, 
mean instantaneous velocity of single DAT-QDs was considerably slower than that of 
nonspecifically bound AMP™ QDs with a mean instantaneous velocity of 0.65 ± 0.02 µm/s 
and 1.27 ± 0.03 µm/s (Figure 6.3 A Middle and Right respectively). Although the visual 
inspection of single DAT-QD trajectories indicated restricted lateral diffusion, their motion 
was uniform and did not contain discrete stop-and-go features on the subsecond timescale 
(Figure 6.3 B), suggesting stable confinement over the time-scale of our measurements 
versus “in and out” microdomain dynamics. To more accurately analyze the diffusion 
pattern of single DAT-QD complexes, we performed the mean square displacement (MSD) 
analysis.48 Individual mean-square displacement (MSD) as a function of time plots for single 
DAT-QD complexes were characterized by pronounced negative curvature at increasing lag 
times, consistent with persistent membrane confinement of DAT proteins (Figure 6.3 C). In 
contrast, MSD of single AMP QDs increased linearly with time, reflecting a Brownian-like 
motion pattern devoid of membrane confinement. 
 
6.2.3. DAT-QD Lateral Diffusion is Highly Restricted in Two Heterologous Expression 
Systems 
To test whether the choice of a heterologous expression system, or the mode of 
expression (transient versus stable transfection), alters membrane DAT mobility, we 
analyzed at least 200 individual real-time trajectories of DAT-QD complexes from 
transiently-transfected HeLa cells (human epithelial cervical carcinoma cells) as well as 
stably-transfected Flp-In 293 cells (human embryonic kidney cells). Sample trajectories are 
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shown in Figure 6.4 A. To assess mean population instantaneous velocity, distributions of 
single step displacements (>10,000 steps for each data set) were fit to a truncated form 
(Cauchy distribution) of the Lévy probability distribution function: 
     [  (  
    
 
)
 
]
  
      [5] 
where x0 is the best-fit instantaneous displacement, a and b are fit coefficients, and the 
goodness of fit is defined by the R2 values, with R2 being greater than 0.95 for all data 
sets.47,49 Unimodality of step size distributions was apparent, and the mean instantaneous 
velocity was determined to be nearly identical for single DAT-QDs in the two cell lines, with 
values of 0.48±0.01 µm/s and 0.51±0.01 µm/s in HeLa cells and Flp-In 293 cells, 
respectively (Figure 6.4 B). Ensemble MSD versus time plots featured pronounced negative 
curvature at increasing lag times, a reliable indicator of restricted diffusive behavior of single 
DAT-QD complexes (Figure 5.4 C). To determine the dimensions of the confinement zone, 
ensemble MSD plots were fit according to the method previously described by Daumas et al.: 
          (    
 
 )           [6] 
where L is the size of the confining domain, τ is the relaxation/equilibration time on short 
timescales, DM is the long-term macroscopic diffusion coefficient, and the goodness of fit is 
defined by the R2 value, with R2 greater than 0.98 for all data sets.50 The average size of a 
putative membrane subdomains restricting lateral diffusion of DAT was determined to be 
150±43 nm and 170±32 nm in HeLa cells and Flp-In 293 cells, respectively (Figure 6.4 D). 
Previous reports have proposed that lateral diffusion of membrane proteins is 
constrained by transient confinement zones (TCZs), such as cholesterol-rich lipid rafts or  
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Figure 6.4. Instantaneous velocity and diffusion behavior of single DAT-QD 
complexes in HeLa and Flp-In 293 cells. (A) Example trajectories. Scale: 1 pixel = 200 
nm. (B) Comparison of instantaneous velocity distributions of single DAT-QD complexes in 
HeLa and Flp-In 293 under basal conditions. Each histogram comprises at least 10,000 
individual displacement steps. (C) Plots of MSD as a function of time. Each plot is based on 
at least 200 individual trajectories acquired during at least three independent experiments. 
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(D) Comparison of the confining domain length (L, nm) restricting the diffusion of single 
DAT-QDs in HeLa and Flp-In 293 cells. Domain size is represented as mean ± SEM.  
 
cytoskeletal corrals.51-53 Recently, we demonstrated that the DAT homolog SERT, labeled in 
serotonergic RN46A cells with ligand-conjugated QDs, associates with cholesterol- and 
GM1 ganglioside-rich membrane microdomains where confined lateral diffusion is evident 
under basal conditions.41 Our analyses of surface trafficking of membrane DAT molecules 
are in agreement with these observations and could be demonstrated in multiple transfected 
cell models. Biochemical studies of the past decade have provided evidence that (i) DAT is 
associated and immobilized with cholesterol-rich membrane fractions in transfected cells and 
(ii) that cholesterol modulates DAT activity as well as cocaine binding to DAT.20,24 In 
parallel, multiple lines of evidence suggest that plasma membrane is compartmentalized into 
many small subdomains, ranging from 20 nm to 2 µm in diameter, in which membrane 
protein molecules are confined on the time scale of 1-30 s.47,51-53 In a recent effort, Chang et 
al. demonstrated that QD-labeled ganglioside GM-1, a principal constituent of lipid rafts, 
slowly diffuses within membrane confinement zones (~200 nm) with the dwelling time 
greater than 10 s.47 Our estimate of the diameters of the membrane subdomains restricting 
DAT-QD diffusion (150-170 nm) agree closely with such values, indicating persistent 
confinement of DAT molecules on the millisecond-second timescale.  
To determine whether our SERT observations extend to heterologously-expressed 
DAT proteins, we performed single QD tracking of endogenous GM-1 ganglioside in the 
plasma membrane of HeLa and Flp-In 293 cells to examine the correlation between GM-1 
resident microdomains and DAT diffusion patterns. As seen in RN46A cells, we found 
GM1-QD movement to be highly restricted in both cell lines, matching dynamic behavior 
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Figure 6.5. Diffusion behavior of single ganglioside GM1-QD complexes in HeLa 
and Flp-In 293 cells. (A) Example trajectories. Scale: 1 pixel = 200 nm. (B) Plots of 
MSD as a function of time. Each plot is based on at least 100 individual trajectories 
acquired during at least three independent experiments. (C) Comparison of the confining 
domain length (L, nm) restricting the diffusion of single GM1-QDs in HeLa and Flp-In 
293 cells. Domain size is represented as mean ± SEM. 
 
of DAT expressed in these cells (Figure 6.5A). Consistent with these findings, MSD analysis 
revealed significantly lower mobility that expected for free diffusion of GM1 (Figure 6.5B), 
with mobility essentially identical to that of DAT-QD complexes in these cells. To extract 
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the size of confining domain, ensemble MSD plots were fit according to the method 
described above (Figure 6.5C). The diameters of the confining microdomain were calculated 
to be 185 ± 72 nm and 183 ± 65 nm in HeLa cells and Flp-In 293 cells, respectively, in 
excellent agreement with the size of confinement zones restricting DAT-QD mobility. The 
biological implications of DAT confinement at the nanoscale, particularly when confined to 
membrane microdomains known to support the accretion of regulatory proteins are 
manyfold, as membrane compartmentalization appears to be an evolved strategy to facilitate 
and co-localize biomolecular interactions that can be targeted by intracellular signal 
transduction mechanisms.51. In the future, we should be able to extend our approach to a 
multicolor, multitarget screening platform (e.g., one color of QD labeling a raft component 
and another color of QD bound to the transporter) to provide an effective method of 
dissecting regulated dynamic interactions in real time.  
 
6.2.4. Attention Deficit/Hyperactivity Disorder-Derived DAT Coding Variation Produces 
Altered Transporter Mobility 
Recently, in a screen for genetic changes in DAT in ADHD subjects, we identified 
and characterized the rare human DAT (hDAT) coding variant, R615C.27 DAT 615R is 
located in a highly conserved region of the transporter’s C-terminus that has been previously 
implicated in DAT trafficking regulation (Figure 6.1B).21,54,55 The DAT 615C substitution 
results in a loss of DAT trafficking sensitivity to both protein kinase C activation as well as 
amphetamine treatments. In the same report, we also demonstrated that the DAT 615C 
mutant is hyperphosphorylated and displays altered associations with flotillin- and GM1 
ganglioside-enriched membrane microdomains in stably-transfected Flp-In 293 cells. We 
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sought to test the hypothesis that these behaviors may be supported by disrupted lateral 
diffusion. Example time series of Flp-In 293 cells expressing DAT 615R (wildtype) or 615C 
(mutant) labeled with QDs are shown in Supplemental Video 1 and Supplemental Video 2, 
respectively (Supplementary Materials are freely available at http://www.acs.org) . Visual 
inspection indicated that the majority of QD-DATs in both populations remained largely 
confined over a 1 min time interval. Examples of QD trajectories are shown in Figure 6.6A. 
Several trajectories of QDs immobilized on a glass coverslip are shown for comparison 
(Figure 6.6A, Bottom Row). The obtained trajectories were analyzed, and the combined 
MSD versus time plots for all measured trajectories of QD-DAT615R, QD-DAT-615C, and 
immobilized QDs are shown in Figure 6.6B. All MSD plots showed a characteristic negative 
curvature, indicating confined DAT diffusion in the membrane of Flp-In 293 cells. Figure 
6C compares the distributions of diffusion coefficients (D1-3) derived from individual MSD 
versus time plots. The median diffusion coefficient of QD-DAT 615R (wildtype) was 0.016 
µm2/s (1.6 × 10-10 cm2/s), in the range found for other membrane proteins,32 whereas QD-
tagged DAT 615C mutants exhibited significantly faster diffusion, with the median diffusion 
coefficient of 0.024µm2/s (2.4 × 10-10 cm2/s) (Table 6.1, p<0.001, one-way ANOVA with a 
Dunn’s post hoc test). We then compared the median area explored at 1 second by DAT in 
the plasma membrane and confirmed that the explored area is significantly larger for the 
615C variant (Figure 6.6D; p<0.001, one-way ANOVA with a Dunn’s post hoc test). Figure 
6.6E shows 5 sec displacement vector maps for all QD-DAT 615R and QD-DAT 615C 
trajectories, with initial QD positions located at the origin. Again, QD-DAT 615C 
complexes exhibited greater mobility than their QD-DAT 615R counterparts, as indicated by 
a more scattered distribution and a significantly larger 5-sec radial displacement (p<0.001, 
one-way ANOVA with a Dunn’s post hoc test). Thus, in agreement with our hypothesis, we  
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Figure 6.6. Single-quantum dot tracking of the wildtype DAT 615R variant and the 
attention deficit/hyperactivity-derived DAT 615C variant in Flp-In 293 cells. (A) 
Example trajectories of single DAT 615R-QD and DAT 615C-QD complexes (n ≥ 500 
trajectories from at least 20 cells over the course of at least three independent experiments). 
Trajectories of immobilized QDs on a coverglass (Bottom Row) are shown for comparison. 
(B) Ensemble mean square displacement versus time plots for QD-labeled DAT 615R and 
DAT 615C in Flp-In 293 cells as well as QDs spun-cast on a coverslip. Error bars indicate 
S.D. (C) Cumulative probability plots depicting diffusion rate distributions (one-way 
ANOVA with Dunn’s post hoc test on raw diffusion coefficient values: DAT 615R vs DAT 
615C, ***P<0.001; DAT615R vs Immobilized QDs on a coverslip, ***P<0.001). (D) 
Explored areas at 1 s, shown as color box plot histograms. Median is represented as a line; 
color box represents the 25%-75% interquartile range (one-way ANOVA with Dunn’s post 
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hoc test: DAT 615R vs DAT 615C, ***P<0.001; DAT615R vs Immobilized QDs on a 
coverslip, ***P<0.001). (E) Two-dimensional polar plots of 5 sec radial displacements (d5s) 
of single QD-DAT 615R, QD-DAT 615C, and immobilized QDs normalized to their 
starting coordinates. Radius of a polar plot is 2.8 µm. Mean d5 values were compared using 
one-way ANOVA with Dunn’s post hoc test; ***P<0.001 with respect to QD-DAT 615R. 
Asterisks in D and E denote P<0.001 statistical significance level. 
 
determined that DAT 615C membrane dynamics were characterized by a significantly faster 
diffusion rate, a larger explored membrane area at 1s, and a greater mobile fraction under 
basal conditions. Our data point are consistent with altered DAT 615C basal membrane 
dynamics as contributory to the functional dysregulation observed with the variant.27 Our 
findings are also consistent with previous observations that cholesterol-rich membrane rafts 
play a major role in the capacity for DAT regulation, produced both by endogenous 
signaling pathways and by psychostimulants.18,20,24 
Table 6.1. Comparison of median diffusion coefficients and explored areas at 1 s of 
QD-labeled DAT 615R and DAT 615C variants under basal, methyl-β-cyclodextrin-
treated, and amphetamine-treated conditions in Flp-In 293 cells. 
DAT 
Coding 
Variant 
Experimental 
Conditions 
Trajectories 
Analyzed 
Median D, 
µm2/s 
Median 
Explored Area 
at 1s, µm2 
 
615R 
Basal 584 0.016 0.038 
+ MβCD 251 0.025 0.052 
+ AMPH 273 0.020 0.045 
 
615C 
Basal 550 0.024 0.057 
+ MβCD 265 0.023 0.054 
+ AMPH 259 0.027 0.060 
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6.2.5. DAT-615R and DAT-615C Surface Mobility is Differentially Regulated by Methyl-β-
Cyclodextrin and Amphetamine 
To examine the effects of membrane raft disruption on DAT lateral mobility, we 
utilized methyl-β-cyclodextrin, a commonly used, cholesterol-extracting agent. Previously, 
Adkins et al. were able to mobilize a fraction of the DAT molecules after membrane raft 
disruption with 10 mM methyl-β-cyclodextrin, as measured using ensemble-averaged 
fluorescence recovery after photobleaching (FRAP).24 Furthermore, Sakrikar et al. proposed 
that the disrupted localization of the DAT 615C coding variant away from cholesterol-, 
GM1 ganglioside-, and flotillin-enriched membrane microdomains might be responsible for 
its insensitivity to amphetamine and protein kinase C activation.27 To investigate this 
possibility at the single molecule level, we treated DAT 615R- and DAT 615C- expressing 
Flp-In 293 cells with 5 µM methyl-β-cyclodextrin for 30 min, performed the two-step QD 
labeling protocol, and then acquired confocal time-lapse images. Wildtype DAT 615R 
mobility after membrane raft disruption was characterized by significantly greater diffusion 
coefficient than in untreated cells along with a larger explored area as compared to basal 
conditions (Table 1; Figure 6.7 A-C; p<0.001, one-way ANOVA with a Dunn’s post hoc test). 
Remarkably, methyl-β-cyclodextrin treatment failed to enhance the mobility of DAT 615C  
(Figure 6.7 A-C; p >0.05, one-way ANOVA with a Dunn’s post hoc test), supporting the 
hypothesis that the variant transporter’s functional and regulatory disturbance arises from its 
mislocalization to a compartment where cholesterol content is not a determinant of the 
transporter’s lateral mobility.  Interestingly, as we previously demonstrated that DAT 615C 
exhibits constitutive endocytosis and recycling, as compared with the highly regulated 
intracellular trafficking of DAT 615R, our findings support the idea that membrane 
compartmentalization is critical for normal DAT regulation and that risk for DA-related  
 114 
 
 
 115 
 
Figure 6.7. DAT 615R and DAT 615C membrane diffusion after MβCD-mediated 
cholesterol depletion and amphetamine treatment in Flp-In 293 cells. (A) Example 
trajectories. Scale: 1 pixel = 200 nm. (B) Comparison of diffusion coefficient distributions 
for single DAT 615R-QDs and DAT 615C-QDs under basal, methyl-β-cyclodextrin-treated, 
amphetamine-treated conditions (one-way ANOVA with Dunn’s post hoc test on non-
transformed data: DAT 615R basal vs DAT 615C basal, ***P<0.001; DAT 615R basal vs 
DAT 615R + methyl-β-cyclodextrin, ***P<0.001; DAT 615C basal vs DAT 615C + methyl-
β-cyclodextrin, P =0.4; DAT 615R basal vs DAT 615R + amphetamine, ***P<0.001; DAT 
615C basal vs DAT 615C + amphetamine, P=0.2). (C) Comparison of the distributions of 
explored areas (MSD at 1 s) by single DAT 615R-QDs and DAT 615C-QDs under basal 
and methyl-β-cyclodextrin-treated conditions (one-way ANOVA with Dunn’s post hoc test on 
non-transformed values: DAT 615R basal vs DAT 615C basal, ***P<0.001; DAT 615R 
basal vs DAT 615R + methyl-β-cyclodextrin, ***P<0.001; DAT 615C basal vs DAT 615C + 
methyl-β-cyclodextrin, P=0.2). (D) Comparison of the distributions of explored areas (at 1 s) 
by single DAT 615R-QDs and DAT 615C-QDs under control and amphetamine-treated 
conditions (one-way ANOVA with Dunn’s post hoc test: DAT 615R basal vs DAT 615C 
basal, ***P<0.001; DAT 615R basal vs DAT 615R + amphetamine, **P<0.01; DAT 615C 
basal vs DAT 615C + amphetamine, P=0.7). For each dataset, n ≥ 250 single DAT-QD 
trajectories from at least three independent experiments. Asterisks in B and C denote 
P<0.001 and P<0.01 statistical significance levels respectively.  
 
disorders, here modeled with a genetic variant linked to ADHD, may arise in some 
individuals as a result of DAT mis-targeting to these domains. 
In our initial studies, we also demonstrated that the DAT 615C variant exhibits 
hyperphorsphorylation and a marked insensitivity to amphetamine-induced trafficking.27 
Amphetamine treatments evoke both an acute translocation of DAT to the cell surface, 
seconds after exposure, or cause DAT internalization after minutes of amphetamine 
treatment.17,22,27 Our visualization methods, implemented over a millsecond to seconds time 
scale, should not be influenced my rapid membrane insertion events as QD labeling is 
restricted to proteins labeled at the cell surface. Thus, we treated DAT 615R- and DAT 
615C-expressing Flp-In 293 cells with 10 µM amphetamine for 30 min and then exposed 
cells to the two-step QD labeling protocol. Real-time trajectory analysis of single QD-labeled 
DAT movement revealed a significant increase in amphetamine-treated DAT 615R lateral 
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membrane mobility when compared to basal conditions (Table 6.1; Figure 5.7 B,D; p<0.001, 
one-way ANOVA with a Dunn’s post hoc test). In contrast, DAT 615C proteins are already as 
mobile as wildtype DAT 615R proteins treated with amphetamine and amphetamine 
treatments produce no further effect on DAT 615C lateral diffusion (p>0.05, one-way 
ANOVA with a Dunn’s post hoc test). Although not a focus of this study, we suspect that the 
failure of amphetamine to increase the diffusion rate of DAT 615C reflects an untethering of 
the variant transporter from critical protein associations that normally both localize the 
transporter to membrane microdomains and that place the transporter in a 
dephosphorylated state, awaiting regulatory phosphorylation as a result of amphetamine 
application,. In relation to the site of the DAT 615C variant in the transporter’s distal C-
terminus, we recently provided evidence that single QD imaging of SERT surface mobility is 
supported by the transporters C-terminus.41 Rao et al., using  ensemble-averaged 
fluorescence recovery after photobleaching, demonstrated increased AlexaFluor488-DAT 
lateral mobility in filopodia of postnatal DA neurons after 60 µM amphetamine treatment 
for 30 min.56  These authors  hypothesized that this increase in DAT mobility could be 
attributed to amphetamine-induced, calcium/calmodulin-dependent protein kinase II-
mediated phosphorylation of the DAT N terminus and subsequent untethering of DAT 
molecules from interacting proteins/lipids.  In support of this model, we demonstrated that 
DAT 615C is hyperphosphorylated on the transporter’s N-terminus .16,27 Our single molecule 
imaging approach should provide a high resolution approach to exploration of how the 
structure and protein interactions of the DAT C-terminus influence the regulatory control of 
DAT exhibited by the transporter’s C-terminus.  
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6.3. Summary and Conclusions 
The goal of this study was to establish a generalizable strategy for evaluation of the plasma 
membrane dynamics of the cocaine- and amphetamine-sensitive DAT protein with the 
nanometer resolution required to monitor transporters localized to membrane subdomains. 
Our single QD-based imaging approach enabled us, for the first time, to detect the lateral 
mobility of individual DAT-QD complexes in living cells and to assess transporter responses 
to microdomain destabilization, a disease-associated mutation, and an addictive 
psychostimulant also used in the treatment of ADHD.  Our data show that the movement 
of transporter molecules in the plasma membrane in several cell expression platforms to be 
highly restricted, with the confinement zone size in close agreement with the previously 
reported dimensions for lipid raft and cytoskeletal corrals and that detected for SERT in 
neuronal RN46A cells. .Consistent with these measures, analysis of single GM1-QD real-
time trajectory data revealed that the diffusion patterns of QD-bound DAT and GM1 
ganglioside molecules are identical. Finally, real-time, single DAT-QD trajectory analysis 
revealed that plasma membrane dynamics of the ADHD-associated DAT R615C coding 
variant exhibits a significantly higher diffusion rate, a larger explored membrane area, and a 
greater mobile fraction under basal conditions. In response to cholesterol extraction and 
amphetamine stimulation, single DAT 615C molecules fail to exhibit altered mobility, likely a 
result of the transporter’s mislocalization and consequent elevation in basal mobility. We 
hypothesize that the higher basal mobility of the mutant transporter reflects an untethering 
of the variant transporter from C-terminal directed or regulated protein associations that 
normally serve to localize the transporter to membrane microdomains. Identifying these 
proteins may offer additional clues to DA regulatory perturbations supporting ADHD risk. 
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6.4. Experimental Section 
6.4.1. Materials 
DMEM, FBS, Hygromycin B, AMP™ QDs and SavQDs (emission max at 655 nm) were 
from Life Technologies. Amphetamine, methyl-β-cyclodextrin, poly-D-lysine, and BSA were 
purchased from Sigma-Aldrich. Four-well chambered coverglass dishes were purchased from 
Lab-Tek. IDT307 and IDT444 were synthesized as previously described.  
 
6.4.2. Cell culture, transfections, and stable cell line generation 
Flp-In 293 cells were used to generate stable lines expressing either DAT 615R or DAT 
615C following the manufacturer’s protocol (Life Technologies). Flp-In™ 293 cell line is 
designed for rapid generation of stable cell lines that ensure high level expression of the 
protein of interest from a Flp-In expression vector. These cells contain a single stably 
integrated FRT site at a transcriptionally active genomic locus. Targeted integration of a Flp-
In expression vector ensures high-level expression of the gene of interest. The Flp-In 293 
host cell line (Invitrogen) was grown in complete medium (D-MEM with 2 mM L-
glutamine, 10% FBS, 1% pen/strep) supplemented with 100 μg/mL Hygromycin B in a 37 
°C incubator with 5% CO2. The wild-type or mutant human DAT (hDAT) cDNA cloned in 
the pcDNA5/FRT expression vector was transfected into Flp-In-293 cells using the Fugene 
6 transfection reagent (Roche, NJ). After 48 h recovery, the cells were grown in medium 
with 100 μg/mL hygromycin B added for several weeks to select for resistant cells where the 
cDNA construct had been recombined into the Flp-In site in the Flp-In-293 cells. HeLa cell 
line (ATCC #CCL-2) was grown in complete medium (D-MEM with 2 mM L-glutamine, 
10% FBS, 1% penn/strep) in a 37°C incubator with 5% CO2. For transient transfection 
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experiments, HeLa cells were grown in complete medium in absence of penn/strep. 24 
hours after seeding HeLa cells, non-expressing (Sham) and DAT-expressing pcDNA3 
vectors containing the SV40 origin and early promoter region for episomal replication were 
introduced into HeLa cells. Fugene HD (Roche, NJ) was used to facilitate transient 
transfection according to the manufacturer’s recommendations. The cells were allowed 24 
hours post-transfection for successful expression of DAT.  
 
6.4.3. QD Labeling of DAT-expressing Flp-In 293 cells 
DAT 615R- or DAT 615C-expressing cells were seeded in poly-D-lysine coated Lab-Tek 
slides and grown for 24 hours. QD labeling was implemented via a two-step protocol. Cells 
were washed twice with warm Krebs’–Ringer’s–HEPES (KRH) (130 mM NaCl, 1.3 mM 
KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, pH 7.4) buffer and 
incubated with a sub-saturating IDT444 concentration of 10 nM in KRH at 37°C and 5% 
CO2. Following two washes with warm KRH, cells were then incubated with a 50 pM dose 
of SavQDs in warm phenol red-free DMEM/2% bovine serum albumin (imaging buffer), 
washed three times with warm imaging buffer, and used for time-lapse image series 
acquisition. To perform cholesterol depletion, methyl-β-cyclodextrin was added to Flp-In 
293 cells to a final concentration of 5 µM (30 min incubation at 37°C and 5% CO2). Cells 
were then washed three times with warm KRH, subjected to the QD labeling protocol, and 
imaged. Amphetamine was administered in an analogous way, with a final effective dose of 
10 µM (20 min incubation at 37°C and 5% CO2). Amphetamine-treated cells were washed 
three times with warm KRH, subjected to the QD labeling protocol, and imaged in presence 
of 10 µM amphetamine.  
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6.4.4. Ganglisoide GM1-QD Tracking 
Ganglioside GM1 labeling and tracking was performed as previously described.47 Briefly, 
cells were incubated with 50-200 nM biotinylated cholera toxin b subunit (CTxB, Sigma-
Aldrich, St. Louis, MO) for 5 min prior to 5 min SavQD655 incubation at 37°C. Data 
acquisition was performed immediately after the final wash step to prevent endocytosis of 
GM1-QD complexes.   
 
6.4.5. High-Speed Confocal Microscopy 
For high speed line-scanning confocal microscopy, images were obtained on a Zeiss LSM 5 
Live confocal system and viewed with a Zeiss 63×/1.4 NA oil immersion objective lens. 
Excitation was provided by a 488 nm 100-milliwatt diode laser. Imaging was performed at 
37°C. QD fluorescence was collected using a long pass 650 filter. Single QD tracking was 
performed at a scan rate of 10 Hz for 1 min. Data were obtained within 10 minutes of the 
final wash step after QD labeling. 
 
6.4.6. Data Analysis 
 Individual TIF images were extracted from sequence files and recompiled as 8-bit image 
stacks by using ImageJ (National Institutes of Health, Bethesda, MD). Image analysis and 
trajectory construction were performed using IDL software (Research Systems, Boulder, 
CO) with algorithms available as shareware at 
http://www.physics.emory.edu/faculty/weeks/. The localization accuracy of the central 
position of the QD in our imaging approach was estimated to be ±10−15 nm.47 The 
uncertainty of the fitted coordinate was estimated (Δσ) via Δσ ≈ w/SNR (nm), where w 
(width) is approximately equal to the wide-field diffraction limit (which for visible light is 
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about 250 nm) and SNR is signal-to-noise ratio defined as SNR = I0 / (σbg
2 + σI0
2)1/2, where 
I0 is the maximum signal intensity above background, σbg
2 is the variance of the background 
intensity values, and σI0
2 is the variance of the maximum signal intensity above the 
background. Intermittency of QD fluorescence was used to verify that single fluorophores 
were analyzed, and extracted trajectories were at least 5 s in length. Trajectories were 
considered continuous if a blinking QD was rediscovered within a 3-pixel radius and 10-
frame window. For each trajectory, mean square displacement (MSD), r2(t), was computed as 
follows: 
〈       〉  
 
   
∑ {[                 ]  [                 ] }
     
   
 
                     [7] 
where δt is the temporal resolution of the acquisition device, (x(jδt), x(jδt)) is the particle 
coordinate at t = jδt, and N is the number of total frames recorded for an individual particle. 
The median MSD (at t = 1 s) of the QD population represents the area explored within 1 s. 
Individual microscopic diffusion coefficient D was determined by fitting the first 1-3 points 
of the MSD versus time curves with the equation:  
〈     〉                      [8] 
This fit is generally used because it determines D independently of the type of motion.57,58 
The distribution of explored area (at t = 1 s) was represented as box plot histograms with 
median, 25% and 75% interquartiles, and the distribution of D1-3-values for each 
experimental condition was displayed as either cumulative probability histograms or vertical 
bar histograms fitted to a unimodal or bimodal Gaussian function. The optimal bin size was 
evaluated using the Friedman-Diaconis rule. Statistical significance of differences in median 
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values was determined using the one-way ANOVA with Dunn’s post hoc test on non-
transformed values. 
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CHAPTER VII 
 
SUMMARY AND FUTURE DIRECTIONS 
 
In this research, I utilized a DAT-specific, biotinylated IDT444 cocaine analog, 
which accesses the high-affinity binding site of DAT and enables subsequent DAT 
recognition with streptavidin-conjugated QDs, to (i) to visualize membrane-bound DAT 
molecules in single live cells, (ii) to develop a fluorescence-based assay that is aimed at 
facilitating high-content screening for novel DAT modulators, (iii) to quantify single-
molecule diffusive behavior of DAT in the plasma membrane of live cells, and (iv) to 
investigate the effects of the attention deficit/hyperactivity disorder-derived coding variation 
in DAT and pathway-specific pharmacological perturbations on DAT plasma membrane 
dynamics in heterologous model expression systems. In particular, my recent data suggest 
that dopamine transporter molecules are subject to complex, dynamic regulation in the 
plasma membrane that may be mediated by key protein-protein interactions and facilitated 
by the plasma membrane compartmentalization. Since all of the dynamic imaging data has 
thus far been acquired in heterologous cell cultures, it is logical that one of the immediate 
questions to be tackled is whether DAT dynamic properties in primary neuronal cultures are 
consistent with our current findings. Another promising research avenue to be explored is 
the use of multicolor QD tracking to confirm existing and identify novel dynamic 
interactions of DAT molecules with various membrane protein (protein kinases, dopamine 
receptor, integrin, synaptic scaffolding elements) and lipid (ganglioside GM1, phospholipids) 
molecules. To this end, it might be Furthermore, our results described in Chapter V of this 
dissertation pinpoint to a critical effect of the DAT C-terminus coding variation on DAT 
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plasma membrane dynamics as well as its functional state. However, it is still unclear how 
the rate of DAT plasma mobility and confinement regime are correlated with the transport 
rate of dopamine, the native substrate of DAT. As such, studies that monitor the rate of 
uptake of a fluorescent false neurotransmitter or a fluorescent transporter substrate (IDT 
307) and assess DAT diffusive behavior in parallel are warranted. To perform such a study, a 
silent QD labeling strategy that minimally perturbs the substrate uptake by DAT must be 
designed. Additionally, it is of utmost importance to determine how other coding variations 
of the conserved amino acids in the DAT N- and C-termini affect DAT lateral diffusion and 
functionality.  
To conclude, quantum dots are swiftly becoming an indispensible tool for molecular 
neurobiological research. In particular, quantum dot technology is experiencing a markedly 
increased use to establish molecular mechanisms of disease and at the same time to facilitate 
next-generation drug discovery. The varieties of commercially available quantum dots for the 
research community will continue to expand, and multifunctional nanoparticles will become 
readily available, such as the nanoparticles that can be used for dual imaging modalities.  We 
believe that the future of quantum dots in biology is exceptionally bright.  
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APPENDIX A 
 
QUANTUM DOT APPROACHES FOR TARGET-BASED DRUG SCREENING 
AND MULTIPLEXED ACTIVE BIOSENSING 
 
A.1. Introduction 
Since their introduction to the field of biology in the mid-1990s, luminescent 
semiconductor nanocrystals, colloquially known as quantum dots, have secured an important 
niche in the field of fluorescence detection and visualization of molecular targets at the 
nanoscale.1,2 Owing to their unique photophysical properties, QDs are now routinely 
employed as cellular and molecular fluorescent reporters of first choice.3-5 In addition to 
ensemble and single-molecule target detection, QD use has been successfully extended to 
such applications as single-particle tracking, intracellular drug delivery, fluorescence 
resonance energy transfer (FRET)-based sensing, and multimodal molecular/tissue 
imaging.3-20 QD photophysical properties are dictated by the inorganic semiconductor 
materials comprising the nanometer-sized (2-10 nm) crystalline core. The QD core is 
composed of a few hundreds to thousands of atoms of semiconductor materials in group II-
VI (e. g., CdS, CdSe, CdTe) and group III-V (e. g., InP, InAs).5,21 The core particle is 
typically passivated with a one- to two-layer thick shell of wider band-gap semiconductor 
material to improve QD stability and enhance their photoluminescence quantum yield by 
eliminating the surface defects at the core/shell interface.21,22 For instance, the shell of choice 
in the case of CdSe core particle is ZnS, leading to quantum yield enhancements up to 300%. 
QD optical properties, which are governed by quantum confinement effects, can be 
effectively tuned through varying core particle size, composition, and morphology. 
Compared to traditional fluorophores, QDs are characterized by unparalleled resistance to 
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photobleaching and excellent brightness, a product of high quantum yields (0.1-0.8 in visible 
region) and large molar absorption coefficients (105-106 M-1cm-1).23,24 Broad absorption 
spectra and narrow, symmetric emission spectra (30-70 nm) of QDs offer great flexibility in 
excitation wavelength selection and enable efficient multicolor experiments, wherein one can 
successfully resolve signals from up to twelve spectrally distinct QDs simultaneously.25 
Another important feature of QDs is their large surface area and surface functionalization 
versatility that allow orthogonal attachment of multiple target recognition and active 
biosensing elements to the central QD nanoscaffold.26 As a result, such functionalized 
nanocrystals can actively sense multiple signal transduction cascades simultaneously and 
combine several functionalities into a multimodal nanoplatform. Although QDs have proven 
to be potent, passive fluorescent reporters in cellular and molecular labeling applications, 
their use in target-based drug discovery assays and active biosensing has only recently been 
actively researched. Here, we will briefly address the versatility of QD surface 
functionalization and then discuss recent advances in drug screening- and biosensing-
oriented applications. 
 
A.2. Quantum Dot Surface Functionalization 
Core/shell nanocrystals (e. g., CdSe/Zns) are typically synthesized in high-
temperature, nonpolar, organic coordinating solvents to ensure best crystalline quality, size 
monodispersity, and optimal photoluminescence properties.27-29 Due to the hydrophobicity 
of native surfactants (trioctylphosphine oxide, TOPO; hexadecylamine, HDA), the as-
prepared core/shell QDs do not possess intrinsic aqueous solubility and must be further 
functionalized to provide a hydrophilic interface that ensures optimal compatibility with 
biologically relevant environment. As such, QDs must be rendered water-soluble through 
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either the ligand cap exchange or heterofunctional polymer shell encapsulation. The ultimate 
goal of QD solubilization is to obtain a nanoscaffold that (i) possesses long-term stability in 
physiologically relevant pH and ionic strength ranges, (ii) contains reactivity handles 
necessary for further bioconjugation, (iii) and exhibits minimal nonspecific interactions with 
biological systems. In the ligand exchange approach, QD native surfactants are displaced 
with hetero-bifunctional ligands that possess a functional group with high affinity to the QD 
surface (e.g., thiols, amines, phopshines) on one end and a hydrophilic functional group to 
aid in water solubility. Thiolated carboxylic acids are routinely selected as the capping ligands 
due to their strong binding affinity to the surface QD semiconductor atoms (e.g., 3-
mercaptopropionic acid, MPA; dihydrolipoic acid, DHLA).4 In addition, a poly(ethylene 
glycol) (PEG) spacer is routinely incorporated into the ligand structure and QD architecture 
to minimize nonspecific binding.30 The disadvantage of the ligand exchange approach is a 
significant reduction in QD photoluminescence quantum yield and reduced long-term 
stability due to the gradual loss of capping ligands from the QD surface. To date, the best 
and most prevalent approach for rendering QD water-soluble and biocompatible while 
minimizing the loss of original photophysical properties is encapsulation in a 
heterofunctional, amphiphilic polymer shell. In this strategy, native QD surfactants are 
retained and facilitate the association of the QD surface with polymer side chains via 
hydrophobic interactions.31-33 As a result, the original, ligand-capped QD scaffold and its 
photophysical properties are minimally perturbed. 
Once QDs are rendered water-soluble, they must be functionalized with surface elements 
that enable specific recognition of cellular biological targets. The key criteria for a successful 
conjugation of a biologically active probe to the QD surface are (i) conjugate stability, (ii) 
retention of biological activity, and (iii) controlled, reproducible display of probes on the QD 
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surface. To this end, several conjugation methodologies have been developed and are 
primarily categorized as either covalent conjugation or noncovalent self-assembly. In a 
conventional covalent conjugation approach, a carboxyl, amine, or thiol group at the QD 
surface is coupled to a desired biomolecule (proteins, peptides, nucleic acids, small 
molecules) with the use of hetero-bifunctional crosslinkers, such as 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and succinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (SMCC). Moreover, recent advances in bioorthogonal chemistry 
provide highly chemoselective and well-controlled alternatives to conventional covalent 
conjugation strategies, such as strain-promoted azide-alkyne cycloaddition, alkene-tetrazine 
ligation, and the Staudinger ligation.26 Currently, noncovalent self-assembly strategies are 
arguably the most popular means of presenting a functional biomolecule on the QD surface 
due to improved control over conjugate valence, biological activity, and binding specificity. 
The most commonly used methodologies involve the use of a biotin-streptavidin 
noncovalent interaction and spontaneous self-assembly of polyhistidine tags on the QD 
surface via metal-affinity interactions.26, 34-36 
 
A.3. Quantum Dot-Based Pharmacological Assays 
Minimal nonspecific interactions, relatively small QD size, high target specificity, and 
superior resistance to degradation allow QD-based ensemble and single-molecule detection 
of extra- and intracellular targets with unprecedented spatiotemporal resolution. 
Consequently, QD-based cellular imaging has emerged as an important tool to unravel the 
molecular details of biological processes. Recent efforts have focused on the application of 
QD technology to the drug discovery process (Table A.1). Superior photophysical features 
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Table A.1. Quantum dots in biosensing applications of pharmacological relevance.  
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of QDs combined with the latest advances in the state-of-the-art high content, automated 
microscopy permit the development of high throughput screening (HTS) assays that enable 
high-resolution, real-time, dynamic analysis of live cells. As QDs considerably simplify the 
technical requirements for a cell-based drug-discovery process, the application of QD 
technology to facilitate automated drug screening is inevitable.  
To date, several formats of QD-based platforms amenable to the drug-discovery 
process have been reported. Our work has focused on the development of target-based, QD 
fluorescence assays to facilitate the discovery of small-molecule modulators of the 
monoamine neurotransmitter transporters (MATs), a family of integral plasma membrane 
proteins that regulate extracellular concentrations of monoamine neurotransmitters and are 
sites of action for widely prescribed antidepressants and psychostimulant drugs.37-46 Our 
ultimate goal is the discovery of novel drugs that exhibit antidepressant-like properties and 
expand the arsenal of currently available therapeutics for combatting mental disorders. The 
cornerstone of our strategy lies in the use of antagonist-conjugated QD nanorpobes, which 
specifically target the primary binding site of MATs, such as serotonin transporter (SERT) 
and dopamine transporter (DAT) (Figure A.1). In our initial SERT labeling effort, the QD 
probe architecture was based on a central CdSe/ZnS core/shell scaffold with thiolated, 
PEGylated serotonin molecules assembled on its surface via ligand exchange of the native 
TOPO surfactants.37 These multivalent, serotonin-terminated QD probes were then used to 
detect plasma membrane SERTs in living human embryonic kidney (HEK) cells (Figure 
A.1). Furthermore, these probes were utilized for subsequent electrophysiological studies, 
wherein biologically active QD probes induced transporter currents in an antagonist-like 
manner. Over time, our labeling strategy has evolved to include the biotin-streptavidin 
noncovalent assembly and a target-specific organic ligand. The use of these components 
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Figure A.1. Biologically active, serotonin-conjugated QDs for serotonin transporter 
(SERT) labeling in living HEK cells. (a) Fluorescence image of SERT-expressing in the 
membrane is indicated by characteristic green fluorescent halos. (b) Electrophysiological 
transporter currents induced by serotonin and biologically active, serotonin-conjugated QDs. 
Serotonin-functionalized QDs elicit an antagonist-like current, as opposed to serotonin 
itself. (c) Structure of the serotonin ligand used to functionalize QDs. Reprinted with 
permission from Ref 37. Copyright 2002 American Chemical Society. 
 
considerably enhanced specificity and sensitivity of transporter recognition and resulted in 
much more streamlined and robust assay protocols. Currently, the organic ligand that serves 
as a bridge between the transporter protein and QD probe is composed of the following 
elements: (i) a high-affinity parent drug that enables recognition of specific binding sites 
within the transporter structure, (ii) a hydrophobic alkyl spacer which permits sufficient 
flexibility and provides a hydrophobic interface for a successful drug-binding pocket 
interaction, (iii) a PEG polymer that aids in aqueous solubility and abolishes possible 
nonspecific interactions with the plasma membrane, and (iv) a biotin moiety that allows 
subsequent QD recognition upon the transporter binding event (Figure A.2). The modular 
design of our tailored organic ligands results in an exceptional degree of control over 
modulating the free energy/temporal stability of the binding interaction as well as carefully 
selecting which specific binding site is targeted. Labeling of surface proteins with these 
probes is done via a two-step labeling protocol. The cells expressing a target protein are 
initially incubated with a biotinylated ligand, and then subsequently labeled with streptavidin- 
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Figure A.2. Structure schematic of tailored organic ligands targeting plasma 
membrane monoamine transporters. Shown here is the general modular probe design 
(top) and examples of active drug ends (in blue) successfully conjugated to the biotinylated 
linker (top). Bottom left: a drug end of  SERT-specific ligands based on the indoleamine-
derived parent drug; bottom right: a drug end of a DAT-specific ligand based on the 
phenyltropane-derived parent drug. 
 
conjugated QDs.  By using the two-step protocol the biotinylated ligand is not subject to 
steric hindrance and retains flexibility to bind to the target, whereas pre-forming ligand-QD 
complexes typically results in multivalent probes with significantly reduced avidity, most 
likely due to unfavorable interactions between streptavidin molecules and biotinylated 
ligands (unpublished data). Additionally, it is difficult to control the number and orientation 
of ligands bound/pre-conjugated to QDs, as commercially available QDs typically present 5-
10 tetravalent streptavidins on the surface. The optimal strategy to prevent multivalent 
interactions between the QD probes and target proteins is to conjugate a single monovalent 
streptavidin to the QD surface, a method pioneered by Alice Ting and colleagues.47,48  
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A.3.1. The Displacement Assay 
Photostability, exceptional optical properties, and excellent specificity of these 
antagonist-conjugated QDs enable several fluorescence-based, pharmacological assay 
formats that utilize a target-based, active configuration (Figure A.3a). In an active continuous 
(displacement) assay format, living cells/oocytes expressing membrane transporters are 
initially labeled with QD conjugates resulting in the “on” fluorescence signal. Next, a drug 
candidate, which may bind to an allosteric binding site, is added, and continuous, real-time 
fluorescence signal measurement is initiated. A positive drug candidate hit induces a protein 
conformational change and initiates QD conjugate displacement upon binding to the 
transporter. Consequently, fluorescence signal is significantly reduced and attains the “off” 
state. The key requirements for the QD conjugates to be successfully employed in a 
displacement assay format are (i) the reversibility of the binding interaction and (ii) 
micromolar affinity of the organic ligand for the transporter. As a validation of the 
displacement assay format, Chang et al. focused on an oocyte model expressing human 
SERT (hSERT), a primary target for drugs used to treat major depressive disorder (Figure 
A.4).44 A QD-tagged indoleamine derivative (IDT318), which is structurally similar to 
serotonin, was used to access the primary neurotransmitter binding site of hSERT. Then, 
paroxetine, an antidepressant drug known as Paxil™ and hypothesized to bind to the 
allosteric site, was used to trigger displacement of the QD conjugates in a dose-dependent 
manner. Continuous signal measurement via widefield fluorescence microscopy readily  
 136 
 
 
Figure A.3. Possible configurations of a target-based drug screening assay employing 
QDs. (a) In an active continuous format, target protein-expressing cells are initially 
incubated with antagonist-conjugated QD probes, resulting in an “ON” fluorescence signal. 
A competitive or an allosteric inhibitor candidate is then added, and the induced 
displacement of antagonist-conjugated probes is indicated by fluorescence loss, resulting in 
the “OFF” signal. (b) In an active endpoint format, target-protein expressing cells are 
initially exposed to a drug candidate, which may block subsequent QD probe binding, 
resulting in the “OFF” signal. In contrast, the parallel control sample is characterized by the 
“ON” fluorescence signal. (c) In a passive format, a QD probe initially targets the 
extracellular domain of the target protein, removed from the primary binding site. 
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Administration of an agonist leads to target protein-QD complex internalization, resulting in 
the endosomal accumulation of QDs. The extent of internalization is quantified via assessing 
assessing the amount of bright endosomal puncta accumulated. 
Figure A.4. QD-based fluorescence displacement assay aimed at the discovery of 
allosteric antidepressants. (a) Representative fluorescence time series, (b) time-dependent 
fluorescence intensity plots, and (c) dissociation kinetics plot sshow the effect of paroxetine, 
suggested to be an allosteric selective serotonin reuptake inhibitor (SSRI), on the interaction 
between ligand-conjugated QD probes and membrane SERT molecules. QD probes are 
readily displaced in the presence of 10 µM and 20 µM doses of paroxetine as opposed to the 
buffer control. Compound activity is determined based on the drug-induced dissociation 
kinetics. Reprinted with permission from Ref 44. Copyright 2011 American Chemical 
Society. 
 
allowed extraction of an apparent dissociation rate constant, an important parameter in 
antidepressant drug screening. This QD-based displacement platform was found to possess 
sensitivity necessary for antidepressant drug screening; its throughput can be increased more 
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than 100-fold when used in conjunction with a commercially available, multiwell-plate 
imaging system.  
 
A.3.2. The Active Endpoint Assay 
When the binding interaction between the QD conjugates and membrane 
transporters is pseudo-irreversible and is characterized by nanomolar affinity, an active 
endpoint assay format is feasible (Figure A.3b). In this format, live cells expressing 
membrane transporters are initially incubated with a drug candidate and subsequently labeled 
with antagonist-conjugated QD probes in the presence of the drug candidate. A positive 
drug candidate hit causes the loss of surface transporters available for QD conjugate binding 
either via blocking the binding site (orthosteric or allosteric) or eliciting transporter 
endocytosis. Consequently, fluorescence signal is significantly reduced and attains the “off” 
state as opposed to the “on” signal exhibited by the parallel control (untreated) cell 
population. As a validation of the active endpoint assay format, Kovtun et al. employed a 
biotinylated, pegylated, high-affinity dopamine transporter (DAT) antagonist β-CFT (2-β-
carbomethoxy-3-β-(4-fluorophenyl)tropane (IDT444), characterized by structural rigidity, 
pharmacological properties resembling those of cocaine, and the IC50 value of ~50 nM.
42 
DAT is a major target for the psychostimulants (cocaine, amphetamine), and abnormalities 
in DAT structure have been linked to a variety of neurodegenerative and psychiatric 
disorders, including schizophrenia, bipolar disorder, Parkinson’s disease, and attention 
deficit/hyperactivity disorder.49-54 Consequently, discovery of novel DAT function 
modulators is a high-priority task, as they represent a promising category of therapeutics in 
the light of increasing global incidence and socioeconomic burden of mental disorders linked 
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to dopamine signaling dysregulation. To this end, Kovtun et al. exploited excellent specificity, 
high affinity, and pseudo-irreversible binding mode of the IDT444-conjugated QDs to 
develop an active endpoint assay targeting DAT.45 As a proof of principle, live, DAT-
expressing HEK293 cells were initially titrated with increasing concentrations of GBR12909 
(a high-affinity DAT antagonist) and phorbol 12-myristate 13-acetate (PMA; a protein kinase 
C activator) and subsequently exposed to IDT444-conjugated QDs. A commercially 
available benchtop flow cytometer was used for fluorescence signal detection and permitted 
a rapid, multiwell, single-cell analysis of multiple, large populations (thousands) of individual, 
QD-labeled cells in parallel. As expected, the fluorescence signal was significantly reduced in 
the presence of GBR12909 and PMA due to the direct antagonism and acute DAT surface 
loss respectively. The QD median intensity parameter was used to generate inhibitory dose-
response curves of DAT modulators, and the extracted IC50 values were found to be in 
excellent agreement with literature values. Furthermore, the use of a commercially available 
flow cytometer system readily allows the miniaturization of the assay to the 384-well plate 
format and represents a promising tool to aid in the initial stages of high throughput 
screening of novel DAT modulators.  
 
A.3.3. The Passive Assay 
In the case of a target-based passive configuration, a central QD scaffold is 
conjugated to an antibody against the extracellular domain sequence or a genetically 
engineered surface fusion tag of a membrane protein (Figure A.3c). In this configuration, it 
is possible to monitor agonist-induced internalization of the target protein with minimal 
interference from the QD tag, hence the descriptor “passive”. The endosomal accumulation 
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of QD-protein complexes leads to the appearance of bright, intracellular fluorescence puncta 
that can be readily quantified via automated image analysis. Recently, Lee and colleagues 
reported a QD-based platform that allowed for real-time monitoring of the agonist-induced 
endocytosis of G-protein coupled κ-opiod receptors (κ-OR), a clinical cancer marker 
overexpressed in several types of carcinomas (Figure A.5).55 The κ-opiod receptor was  
 
Figure A.5. High-content screening of the agonist-induced internalization of κ-opiod 
receptor in human osteocarcinoma cells. (a) Representative human osteocarcinoma cell 
images treated with 1 pM and 100 µM of κ-opiod receptor agonist. (b) The number of spots 
(Qdot fluorescence) within the cytoplasmic region was calculated per cell using automated 
image analysis software, and the resulting EC50 values were obtained from concentration-
dependent plots. Reprinted with permission from Ref 55. Copyright 2012 WILEY-VCH 
Verlag GmbH & Co. 
 
engineered to contain an extracellular influenza hemagglutinin peptide tag, which can be 
specifically recognized by the anti-hemagglutinin antibody, and then overexpressed in human 
osteosarcoma (U2OS) cells. In turn, the hemagglutinin antibody was covalently conjugated 
to the central QD scaffold via SMCC methodology to enable specific, passive labeling of the 
membrane receptors. When exposed to a selective κ-OR agonist, QD-bound receptors 
underwent acute endocytosis within 30 minutes of agonist application. Intracellular 
accumulation of QD-receptor complexes was monitored using an automated fluorescence 
microscope system (Operetta, PerkinElmer, USA), and the obtained dose-response curves 
were used to quantify agonist potency. This report illustrates how a combination of a QD-
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based screening platform with an automated fluorescence imaging system represents a 
promising platform for further drug-screening applications. 
 
A.4. Multiplexed Quantum Dot-Based Biosensing via Förster Resonance Energy 
Transfer 
The ability of the QD nanoscaffold to accommodate multiple copies of biomolecular 
probes and form multivalent, multimodal constructs has been actively exploited in the field 
of biosensing. As a biosensor, QD no longer acts as a passive, persistently “on” tag; instead, 
it participates in a signal transduction cascade via Förster resonance energy transfer (FRET) 
or charge transfer (CT), whereby QD emission intensity is modulated in the presence of 
appropriate donor/acceptor molecules.7 FRET has become a dominant mechanism for QD-
based biosensing, as it is rigorously characterized and exploits key advantages of QDs over 
traditional fluorophores: (i) high quantum yields and large molar extinction coefficients that 
maximize FRET, (ii) narrow, size-tunable emission spectra and broad excitation spectra that 
allow multicolor sensor configurations and minimize spectral cross-talk, and (iii) multivalent 
presentation of donors/acceptors on the central QD scaffold that directly enhances FRET 
efficiency. As such, QDs are ideal FRET donors, and the typical QD-FRET configuration 
includes an organic dye molecule serving as the acceptor fluorophore. Such QD-dye FRET 
pairs have been successfully employed by many groups to sense nucleic acid hybridization, 
detect the presence of ions/analytes in solution, monitor proteolytic enzyme activity, and 
assess competitive receptor binding kinetics.56-63 Until recently, QD use as the acceptor has 
been limited, as it is difficult to circumvent direct optical excitation of QDs due to their 
broad absorption spectra and large molar extinction coefficients. Another complicating 
factor is the long-lived (>10 ns) excited state of QDs compared to that of conventional 
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molecular fluorophores (<5 ns).23 One elegant solution to this challenge has been the use of 
luminescent lanthanide ion donors with millisecond excited state lifetimes.64 Furthermore, 
lanthatnide-QD FRET pairs are characterized by excellent FRET efficiency and large Förster 
radii (~10 nm). Incorporation of the lanthanide ions into the biosensor architecture enables 
efficient energy transfer to the QD acceptor after the QD excited state is allowed to decay 
following direct optical excitation. Taking advantage of the compatibility of excited state 
lifetimes of QDs, dyes, and lanthanides, it has become possible to assemble multistep 
QD/dye/lanthanide FRET relays around the central QD nanoscaffold, whereby QD core 
functions as both a FRET donor and acceptor (Figure A.6).65-68 Recently, Algar et al. reported  
 
Figure A.6. Schematic of a time-gated FRET relay for multiplexed protease sensing. 
A central CdSe/ZnS core/shell Qdot is coated with compact zwitterionic ligands (CL4) and 
assembled with polyhistidine (His6)-appended peptide substrates. The peptides, labeled with 
either Tb lanthanide or Alexa647 dye, serve as substrates, SubTRP and SubChT, for trypsin 
(TRP) and chymotrypsin (ChT) proteolytic enzymes, respectively. The cleavage sites are 
highlighted in the peptide sequences. Proteolytic activity disengages FRET1 and FRET2 
pathways and alters the prompt/gated photoluminescence ratios, which are used as analytical 
signals. Reprinted with permission from Ref 66. Copyright 2012 American Chemical Society. 
 
the use of QDs as a time-gated FRET relay intermediary to achieve multiplexed, 
spectrotemporal detection of proteolytic and nucleic acid binding events.66, 67 In a 
prototypical architecture, multiple copies of Tb3+ ions and AlexaFluor dyes are concentrically 
assembled around the QD nanoscaffold. Tb-to-QD time-gated FRET pathway 1 (FRET1) 
and QD-to-AlexaFluor FRET pathway 2 (FRET2) serve as sensors of parallel, independent 
binding events. In contrast to previous multiplexed QD formats which rely on several colors 
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of QDs, binding event information in this configuration is derived from two independent 
FRET processes and provides the unprecedented ability to simultaneously monitor several 
biological processes using a single color of QD, a significant advancement in the field of 
nanoparticle-based biosensing.  
 
A.5. Conclusion and Future Outlook 
Recent advances in bioconjugation and bioorthogonal chemistry will considerably 
improve the utilization of the large QD surface area, wherein the QD serves as the central 
nanoscaffold for the multivalent assembly of multifunctional biomolecular probes in a 
concentric fashion. Such QD surface functionalization versatility combined with reduced 
size and compact amphiphilic surfactants is the reason multiplexed biosensing of 
intracellular signaling cascades is a swiftly approaching reality. As advanced, high-content 
imaging systems are becoming increasingly commercially available and users are adopting 
QD technology globally, QD-based drug screening and multiplexed biosesing have the 
potential to revolutionize the early stages of the drug discovery process. Furthermore, with 
recent breakthroughs in microfluidic technology, it is no longer merely a fruit of imagination 
that QD-based lab-on-a-chip devices will be routinely used for point-of-care diagnostics. 
Nevertheless, the most pressing issues currently hindering widespread QD use are (i) batch-
to-batch variability in the preparation of application-ready QD constructs, (ii) limited QD 
probe reusability, as most documented applications are conducted in bulk solutions, (iii) 
potential toxicity concerns associated with QD core constituent materials, and (iv) a 
relatively high cost of quantum dot synthesis. Efforts are under way to overcome these 
significant challenges and develop a new generation of low-cost, non-toxic, reproducible, 
and reusable QD-based drug screening assays and bioanalytical sensing technologies.  
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